MeSH term
Frequency | Condition_Probility | Female | 771 | 0.0 |
Humans | 1734 | 0.0 |
Pregnancy | 11 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
Norway | 8 | 7.0 |
Animals | 363 | 0.0 |
Child, Preschool | 34 | 0.0 |
United States/epidemiology | 3 | 0.0 |
Adult | 630 | 1.0 |
Carrier Proteins/*blood | 8 | 3.0 |
Gene Frequency | 63 | 1.0 |
Genetic Heterogeneity | 6 | 2.0 |
Genotype | 116 | 1.0 |
Introns | 5 | 0.0 |
Lipids/*blood | 149 | 26.0 |
Male | 897 | 1.0 |
Middle Aged | 627 | 1.0 |
Mutagenesis, Insertional | 3 | 1.0 |
Phenotype | 85 | 0.0 |
*Polymorphism, Genetic | 82 | 1.0 |
Research Support, Non-U.S. Gov't | 1041 | 0.0 |
Sequence Deletion | 10 | 0.0 |
Apolipoproteins B/*analysis | 21 | 77.0 |
Azo Compounds | 2 | 20.0 |
Fluorescent Dyes | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 636 | 1.0 |
Rosaniline Dyes | 2 | 50.0 |
Aged | 296 | 0.0 |
Apolipoproteins B/*blood | 123 | 76.0 |
Data Interpretation, Statistical | 2 | 0.0 |
Dietary Fats/administration & dosage/pharmacology | 2 | 50.0 |
Hyperlipidemia/*blood | 8 | 20.0 |
Postprandial Period/*physiology | 3 | 9.0 |
Triglycerides/*blood | 41 | 11.0 |
Antioxidants/*pharmacology | 4 | 3.0 |
Arteriosclerosis/*prevention & control | 2 | 11.0 |
*Nutrition | 2 | 5.0 |
Kinetics | 137 | 1.0 |
*Phytotherapy | 3 | 3.0 |
Plant Extracts/*pharmacology | 4 | 5.0 |
Reference Values | 89 | 2.0 |
Amino Acid Sequence | 75 | 0.0 |
Amino Acid Substitution | 7 | 0.0 |
Apolipoproteins B/*chemistry/genetics/*metabolism | 4 | 100.0 |
Binding Sites | 29 | 0.0 |
Cell Line | 86 | 0.0 |
Heparin/*metabolism | 3 | 3.0 |
Mice | 117 | 0.0 |
Mice, Transgenic | 53 | 1.0 |
Models, Molecular | 15 | 0.0 |
Mutagenesis, Site-Directed | 12 | 0.0 |
Protein Conformation | 32 | 1.0 |
Proteoglycans/*metabolism | 6 | 9.0 |
Recombinant Proteins/metabolism | 19 | 0.0 |
Restriction Mapping | 18 | 0.0 |
Transfection | 58 | 0.0 |
Biological Transport | 43 | 3.0 |
Endoplasmic Reticulum/chemistry/metabolism | 2 | 40.0 |
Lipoproteins, VLDL/chemistry/*metabolism | 5 | 50.0 |
Oleic Acid/pharmacology | 12 | 38.0 |
Phospholipids/analysis | 10 | 27.0 |
Rats | 110 | 0.0 |
Tumor Cells, Cultured | 123 | 0.0 |
*DNA Fingerprinting | 3 | 6.0 |
Ethnic Groups | 5 | 2.0 |
Forensic Medicine/methods | 2 | 5.0 |
*Gene Frequency | 12 | 2.0 |
India | 7 | 2.0 |
Minisatellite Repeats/*genetics | 8 | 10.0 |
Polymerase Chain Reaction | 60 | 0.0 |
Germany/epidemiology | 2 | 1.0 |
Lipids/*metabolism | 21 | 9.0 |
Polymorphism, Genetic | 56 | 1.0 |
Variation (Genetics) | 31 | 1.0 |
Apolipoproteins B/secretion | 5 | 62.0 |
Caco-2 Cells | 16 | 4.0 |
Carrier Proteins/*antagonists & inhibitors | 3 | 13.0 |
Dose-Response Relationship, Drug | 35 | 0.0 |
Gene Expression Regulation/drug effects/*physiology | 2 | 2.0 |
Intestines/*metabolism | 17 | 23.0 |
Liver/*metabolism | 31 | 7.0 |
Apolipoproteins B/biosynthesis/*metabolism/secretion | 2 | 100.0 |
Biological Transport/physiology | 3 | 1.0 |
Carrier Proteins/*metabolism | 16 | 2.0 |
Lipoproteins/*biosynthesis | 7 | 53.0 |
Microsomes/*metabolism | 14 | 33.0 |
Particle Size | 52 | 18.0 |
Apolipoproteins B/blood | 120 | 47.0 |
Cholesterol/blood | 209 | 17.0 |
Drug Therapy, Combination | 13 | 0.0 |
Fibrinogen/analysis | 6 | 3.0 |
Hyperlipidemia/*drug therapy | 4 | 13.0 |
Hypertension/*drug therapy | 2 | 1.0 |
Lipoproteins, LDL Cholesterol/blood | 133 | 25.0 |
Triglycerides/blood | 241 | 17.0 |
Apolipoproteins B/metabolism | 55 | 61.0 |
Apolipoproteins E/metabolism | 12 | 19.0 |
Cholesterol Esters/metabolism | 15 | 13.0 |
Electrophoresis, Agar Gel | 20 | 3.0 |
Electrophoresis, Polyacrylamide Gel | 93 | 2.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
Hydrolysis | 20 | 2.0 |
Immunohistochemistry | 13 | 0.0 |
Lipids/metabolism | 25 | 7.0 |
Lipoproteins, LDL/*metabolism | 53 | 28.0 |
Macrophages/*metabolism | 10 | 4.0 |
Mice, Inbred C57BL | 25 | 0.0 |
Microscopy, Electron | 38 | 1.0 |
Phospholipases A/*metabolism | 2 | 4.0 |
Protein Binding | 61 | 0.0 |
Time Factors | 69 | 0.0 |
Apolipoprotein A-I/metabolism | 19 | 26.0 |
Blotting, Western | 33 | 0.0 |
Calcium-Binding Proteins/metabolism | 2 | 2.0 |
Calnexin | 4 | 13.0 |
Carcinoma, Hepatocellular/*metabolism | 7 | 6.0 |
Endoplasmic Reticulum/*metabolism | 12 | 8.0 |
Lipoproteins, VLDL/metabolism | 33 | 31.0 |
Liver Neoplasms/*metabolism | 6 | 6.0 |
Microsomes, Liver/*metabolism | 4 | 2.0 |
Apolipoproteins B/*biosynthesis | 13 | 86.0 |
DNA, Complementary/metabolism | 8 | 0.0 |
RNA/metabolism | 7 | 1.0 |
RNA, Messenger/metabolism | 22 | 0.0 |
Sex Factors | 32 | 2.0 |
Triglycerides/*metabolism | 19 | 22.0 |
Apolipoproteins B/*metabolism | 81 | 81.0 |
Adolescent | 141 | 0.0 |
Apolipoproteins E/*genetics | 41 | 4.0 |
*Body Mass Index | 3 | 3.0 |
Health Surveys | 2 | 2.0 |
Lipids/blood/*metabolism | 3 | 16.0 |
Polymorphism, Genetic/genetics | 6 | 0.0 |
Quebec | 5 | 9.0 |
Risk Factors | 169 | 2.0 |
African Continental Ancestry Group/genetics | 4 | 1.0 |
Coronary Disease/etiology/genetics | 2 | 40.0 |
European Continental Ancestry Group/genetics | 10 | 1.0 |
*Exercise | 2 | 1.0 |
Family Health | 7 | 0.0 |
Lipoproteins/blood | 81 | 20.0 |
Carotid Arteries/*ultrasonography | 2 | 13.0 |
Cohort Studies | 36 | 1.0 |
Cross-Sectional Studies | 29 | 2.0 |
Lipoproteins, HDL Cholesterol/blood | 122 | 17.0 |
Amino Acids | 2 | 6.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology | 4 | 18.0 |
Anticholesteremic Agents/*therapeutic use | 9 | 17.0 |
Double-Blind Method | 42 | 2.0 |
Heptanoic Acids/*therapeutic use | 6 | 24.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use | 7 | 15.0 |
Lipoproteins/metabolism | 12 | 10.0 |
Lipoproteins, LDL/metabolism | 55 | 25.0 |
Pyrroles/*therapeutic use | 6 | 16.0 |
Viscera | 2 | 6.0 |
Carrier Proteins/genetics | 6 | 1.0 |
Case-Control Studies | 43 | 0.0 |
Chromosome Mapping | 21 | 0.0 |
*Chromosomes, Human, Pair 1 | 2 | 0.0 |
Netherlands | 3 | 1.0 |
Analysis of Variance | 42 | 2.0 |
Apolipoproteins/blood/genetics | 3 | 60.0 |
Comparative Study | 235 | 0.0 |
Lipoproteins/*blood/genetics | 5 | 55.0 |
Polymorphism, Genetic/*genetics | 24 | 1.0 |
Apolipoprotein A-I/blood | 31 | 28.0 |
Apolipoproteins E/genetics | 12 | 3.0 |
Cardiovascular Diseases/prevention & control | 3 | 23.0 |
Carrier Proteins/blood | 8 | 7.0 |
Cholesterol Esters/*blood | 12 | 14.0 |
*Estrogen Replacement Therapy | 8 | 7.0 |
Food | 4 | 3.0 |
*Glycoproteins | 47 | 5.0 |
Lipids/blood | 108 | 16.0 |
Lipoprotein Lipase/blood | 7 | 8.0 |
Lipoproteins, LDL/blood | 60 | 25.0 |
Membrane Proteins/blood | 2 | 5.0 |
*Phospholipid Transfer Proteins | 6 | 3.0 |
*Postmenopause | 4 | 6.0 |
Body Composition | 12 | 5.0 |
Densitometry, X-Ray | 3 | 2.0 |
Korea/epidemiology | 2 | 3.0 |
Questionnaires | 6 | 1.0 |
Viral Load | 4 | 0.0 |
Oxidation-Reduction | 55 | 4.0 |
Ultracentrifugation/methods | 6 | 31.0 |
Carcinoma, Hepatocellular/pathology | 2 | 4.0 |
Carrier Proteins/*pharmacology | 2 | 4.0 |
Enzyme-Linked Immunosorbent Assay | 41 | 1.0 |
Child | 92 | 0.0 |
Fatty Acids, Nonesterified/*blood | 3 | 6.0 |
Hyperlipidemia, Familial Combined/*blood | 2 | 22.0 |
Antilipemic Agents/*therapeutic use | 16 | 21.0 |
Drug Evaluation | 2 | 0.0 |
Follow-Up Studies | 26 | 0.0 |
Gemfibrozil/*therapeutic use | 3 | 12.0 |
Patient Compliance | 3 | 1.0 |
Pravastatin/*therapeutic use | 4 | 28.0 |
Treatment Outcome | 16 | 0.0 |
Apolipoproteins B/*genetics/*metabolism | 4 | 66.0 |
Genetic Markers/genetics | 6 | 1.0 |
Homozygote | 26 | 1.0 |
Lipoproteins, VLDL Cholesterol/blood | 17 | 27.0 |
Apolipoproteins/genetics/*metabolism | 4 | 40.0 |
Apolipoproteins B/genetics/metabolism | 6 | 85.0 |
Interleukin-1/*pharmacology | 2 | 0.0 |
Apolipoproteins B/*genetics | 160 | 87.0 |
DNA Mutational Analysis | 6 | 0.0 |
Erythrocytes/metabolism | 3 | 1.0 |
Heterozygote | 52 | 1.0 |
*Mutation | 27 | 0.0 |
Anticholesteremic Agents/pharmacology | 7 | 15.0 |
Apolipoproteins B/*secretion | 22 | 88.0 |
Cysteine Endopeptidases/metabolism | 10 | 4.0 |
Lipids/biosynthesis | 5 | 25.0 |
Lipoproteins, VLDL Cholesterol/metabolism | 2 | 40.0 |
Multienzyme Complexes/metabolism | 8 | 4.0 |
Proteasome Endopeptidase Complex | 24 | 4.0 |
*Tea | 2 | 9.0 |
Diabetes Mellitus, Type 1/*blood/*drug therapy | 2 | 25.0 |
Insulin/blood | 37 | 5.0 |
Lipoproteins, VLDL/*blood | 20 | 28.0 |
Brazil | 2 | 0.0 |
Exons/genetics | 6 | 0.0 |
Hypercholesterolemia/*genetics | 4 | 22.0 |
Mutation/*genetics | 5 | 0.0 |
Mutation, Missense/genetics | 2 | 1.0 |
Receptors, LDL/*genetics | 17 | 10.0 |
Apolipoproteins B/*metabolism/secretion | 5 | 83.0 |
Cholesterol/biosynthesis | 3 | 20.0 |
Models, Animal | 2 | 0.0 |
Models, Biological | 40 | 1.0 |
Rabbits | 39 | 1.0 |
Receptors, LDL/*deficiency/genetics | 2 | 25.0 |
Coronary Disease/*blood | 13 | 19.0 |
Intercellular Adhesion Molecule-1/*blood | 2 | 3.0 |
Solubility | 13 | 0.0 |
Vascular Cell Adhesion Molecule-1/*blood | 2 | 7.0 |
Caco-2 Cells/*metabolism | 3 | 27.0 |
Intestines/metabolism | 10 | 9.0 |
Linoleic Acids/pharmacology | 2 | 33.0 |
RNA, Messenger/biosynthesis | 8 | 0.0 |
Apolipoproteins/*blood | 86 | 55.0 |
Coronary Angiography | 15 | 6.0 |
Lipoprotein(a)/*blood | 41 | 47.0 |
Prognosis | 6 | 0.0 |
Protein Isoforms/blood | 2 | 8.0 |
Survival Rate | 4 | 0.0 |
Sweden/epidemiology | 2 | 1.0 |
Aged, 80 and over | 44 | 0.0 |
*Dietary Supplements | 2 | 3.0 |
Nutrition Surveys | 3 | 14.0 |
Probability | 8 | 1.0 |
Risk Assessment | 7 | 0.0 |
Sensitivity and Specificity | 25 | 0.0 |
English Abstract | 95 | 0.0 |
Genetics, Population | 10 | 2.0 |
Obesity/*genetics | 2 | 1.0 |
Russia | 6 | 6.0 |
Area Under Curve | 4 | 0.0 |
Insulin/administration & dosage/blood | 2 | 40.0 |
Insulin-Like Growth Factor Binding Protein 3/blood | 3 | 5.0 |
Insulin-Like Growth Factor I/analysis | 4 | 3.0 |
Lipoproteins, VLDL/*chemistry | 4 | 100.0 |
Haplotypes/genetics | 3 | 0.0 |
Hypobetalipoproteinemia/*genetics | 13 | 100.0 |
Linkage (Genetics)/*genetics | 3 | 1.0 |
Pedigree | 61 | 0.0 |
Quantitative Trait, Heritable | 3 | 5.0 |
Apolipoproteins B/immunology | 4 | 66.0 |
Hyperlipoproteinemia/blood | 2 | 25.0 |
Lipoproteins, HDL Cholesterol/*blood | 21 | 9.0 |
Lipoproteins, LDL Cholesterol/*blood | 25 | 29.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 91 | 0.0 |
Blood Glucose/analysis | 20 | 3.0 |
Diabetes Mellitus, Type 2/*complications/physiopathology | 2 | 10.0 |
Fasting/blood | 5 | 9.0 |
Insulin Resistance | 10 | 5.0 |
Lipoproteins/*blood | 125 | 21.0 |
Lipoproteins, LDL/*blood/chemistry | 7 | 36.0 |
Peptide Fragments/blood | 3 | 2.0 |
Lipoproteins, LDL/*blood | 70 | 44.0 |
Regression Analysis | 62 | 3.0 |
Apolipoproteins C/*blood | 9 | 29.0 |
DNA Primers | 16 | 0.0 |
Diabetes Mellitus, Type 1/*blood/*genetics | 2 | 66.0 |
Magnetic Resonance Spectroscopy | 5 | 0.0 |
Polymorphism, Genetic/*physiology | 2 | 2.0 |
Reverse Transcriptase Polymerase Chain Reaction | 14 | 0.0 |
Gene Expression | 18 | 0.0 |
Mice, Knockout | 18 | 0.0 |
Microscopy, Fluorescence | 5 | 0.0 |
Apolipoproteins/analysis | 8 | 29.0 |
Disease Progression | 8 | 0.0 |
Receptors, LDL/genetics | 12 | 16.0 |
Administration, Cutaneous | 2 | 2.0 |
Administration, Oral | 6 | 0.0 |
Apolipoproteins/blood | 68 | 29.0 |
Cholesterol Esters/*biosynthesis | 3 | 37.0 |
Culture Media | 8 | 1.0 |
Methionine/metabolism | 10 | 7.0 |
Phenylurea Compounds/pharmacology | 3 | 50.0 |
Sterol O-Acyltransferase/antagonists & inhibitors | 2 | 33.0 |
Biological Markers/blood | 23 | 1.0 |
Longitudinal Studies | 11 | 1.0 |
Proportional Hazards Models | 2 | 0.0 |
Statistics, Nonparametric | 13 | 1.0 |
Exercise Test | 2 | 0.0 |
*Insulin Resistance | 12 | 6.0 |
Apolipoproteins A/blood | 17 | 25.0 |
Diabetes Mellitus, Type 2/blood/*complications | 3 | 15.0 |
Hypertriglyceridemia/blood/*complications | 3 | 42.0 |
Insulin/*blood | 6 | 3.0 |
Proinsulin/*blood | 2 | 18.0 |
Apolipoproteins B/biosynthesis/*genetics | 7 | 87.0 |
Cells, Cultured | 76 | 0.0 |
Cloning, Molecular | 28 | 0.0 |
Cytidine Deaminase/*genetics | 8 | 57.0 |
Molecular Sequence Data | 155 | 0.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
RNA Editing/*genetics | 7 | 41.0 |
RNA, Messenger/*genetics | 9 | 2.0 |
Rats, Sprague-Dawley | 13 | 0.0 |
Sequence Homology, Amino Acid | 11 | 0.0 |
Sequence Homology, Nucleic Acid | 10 | 0.0 |
Apolipoprotein A-I/*analysis | 8 | 72.0 |
Isotope Labeling | 7 | 9.0 |
Lipoproteins/*chemistry | 4 | 40.0 |
Reproducibility of Results | 16 | 1.0 |
1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 8.0 |
Apolipoproteins/*metabolism | 10 | 25.0 |
Enzyme Activation | 3 | 0.0 |
Lipoproteins, LDL Cholesterol/*metabolism | 4 | 20.0 |
Severity of Illness Index | 9 | 0.0 |
*Acetates | 2 | 66.0 |
Apolipoproteins B/*biosynthesis/metabolism/secretion | 2 | 100.0 |
Biological Transport/drug effects | 7 | 2.0 |
Cysteine Proteinase Inhibitors/pharmacology | 10 | 4.0 |
Endoplasmic Reticulum/drug effects/metabolism | 2 | 15.0 |
Enzyme Inhibitors/*pharmacology | 5 | 0.0 |
Golgi Apparatus/drug effects/metabolism | 2 | 22.0 |
Leupeptins/pharmacology | 13 | 10.0 |
Sterol O-Acyltransferase/*antagonists & inhibitors | 4 | 44.0 |
Sulfonic Acids/*pharmacology | 2 | 50.0 |
Antiretroviral Therapy, Highly Active | 3 | 0.0 |
*HIV-1 | 3 | 0.0 |
Interleukin-1/blood | 2 | 1.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Bias (Epidemiology) | 2 | 3.0 |
Linear Models | 12 | 2.0 |
Predictive Value of Tests | 15 | 0.0 |
Reagent Kits, Diagnostic | 3 | 2.0 |
Renal Dialysis | 7 | 2.0 |
Myocardial Ischemia/*genetics | 2 | 20.0 |
Genetic Markers | 28 | 0.0 |
Lipids/*blood/genetics | 3 | 37.0 |
Amino Acids/chemistry | 2 | 1.0 |
Base Sequence | 154 | 0.0 |
Blotting, Northern | 15 | 0.0 |
Cholesterol/metabolism | 26 | 8.0 |
Chromatography, High Pressure Liquid | 9 | 0.0 |
Hepatocytes/metabolism | 2 | 2.0 |
Liver/metabolism | 49 | 6.0 |
Models, Genetic | 10 | 0.0 |
Precipitin Tests | 15 | 0.0 |
Blood Proteins/*analysis | 4 | 2.0 |
Body Mass Index | 60 | 5.0 |
*Complement 3a/*analogs & derivatives | 5 | 25.0 |
Fasting/*blood | 4 | 25.0 |
Leptin/blood | 3 | 5.0 |
Osmolar Concentration | 9 | 1.0 |
Carrier Proteins/*genetics | 21 | 1.0 |
Dietary Fats/administration & dosage | 13 | 14.0 |
Population Surveillance | 2 | 1.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
Sweden | 8 | 3.0 |
DNA, Complementary | 4 | 0.0 |
Exons | 10 | 0.0 |
Promoter Regions (Genetics) | 16 | 0.0 |
RNA, Messenger/genetics | 19 | 0.0 |
Antilipemic Agents/therapeutic use | 4 | 13.0 |
Hyperlipidemia/drug therapy | 2 | 15.0 |
*Renal Dialysis | 11 | 2.0 |
*Kidney Transplantation | 3 | 0.0 |
Prospective Studies | 29 | 0.0 |
Alleles | 100 | 1.0 |
Carrier Proteins/*genetics/metabolism | 4 | 1.0 |
Cholesterol/*blood | 39 | 16.0 |
Linkage Disequilibrium | 7 | 0.0 |
Mutation, Missense | 2 | 0.0 |
Point Mutation | 8 | 0.0 |
Adipose Tissue/metabolism | 7 | 5.0 |
Arteriosclerosis/blood | 5 | 20.0 |
Blood Glucose/metabolism | 15 | 2.0 |
Body Weight | 19 | 2.0 |
Glucose/metabolism | 3 | 1.0 |
Hypertriglyceridemia/genetics | 4 | 26.0 |
Immunoblotting | 21 | 0.0 |
Protein Structure, Tertiary | 9 | 0.0 |
Protein Transport | 3 | 0.0 |
Tissue Distribution | 12 | 0.0 |
Drugs, Chinese Herbal/*therapeutic use | 3 | 3.0 |
Diet | 18 | 5.0 |
Intestinal Absorption | 4 | 2.0 |
Sitosterols/blood | 2 | 100.0 |
Age Factors | 28 | 1.0 |
Apolipoproteins A/*blood | 22 | 50.0 |
Logistic Models | 9 | 1.0 |
Apolipoprotein A-I/*blood | 10 | 31.0 |
Blood Pressure | 26 | 4.0 |
Incidence | 9 | 0.0 |
Taiwan/epidemiology | 4 | 3.0 |
Lipoproteins, LDL Cholesterol/blood/drug effects | 3 | 23.0 |
Diagnosis, Differential | 4 | 0.0 |
Infant | 21 | 0.0 |
Consanguinity | 3 | 0.0 |
Continental Population Groups | 5 | 2.0 |
Gene Frequency/genetics | 3 | 0.0 |
Heterozygote Detection | 5 | 0.0 |
Prevalence | 17 | 1.0 |
Age Distribution | 7 | 2.0 |
Databases, Factual | 2 | 0.0 |
Sex Distribution | 8 | 3.0 |
Haplotypes | 22 | 1.0 |
Korea | 2 | 0.0 |
Chromosomes, Human, Pair 2 | 3 | 1.0 |
Haplotypes/*genetics | 3 | 1.0 |
Microsatellite Repeats | 5 | 0.0 |
Albumins/metabolism | 7 | 4.0 |
Brefeldin A/pharmacology | 2 | 2.0 |
Cell Membrane Permeability | 6 | 3.0 |
Protein Processing, Post-Translational | 15 | 1.0 |
Puromycin/pharmacology | 4 | 14.0 |
Catalysis | 6 | 0.0 |
Lipoproteins/biosynthesis | 3 | 21.0 |
Apolipoprotein A-I/analysis/genetics | 2 | 100.0 |
Apolipoproteins/blood/*genetics | 6 | 37.0 |
Lipoproteins/blood/*genetics | 5 | 71.0 |
Apolipoprotein A-II/blood | 5 | 26.0 |
Aryldialkylphosphatase | 5 | 2.0 |
Postmenopause | 2 | 1.0 |
Fibrinogen/*analysis | 3 | 6.0 |
Hypertension/*blood/complications | 3 | 30.0 |
Alternative Splicing/genetics | 2 | 1.0 |
Colonic Neoplasms/genetics | 2 | 3.0 |
*Cytidine Deaminase | 2 | 66.0 |
RNA, Messenger/analysis/genetics | 2 | 0.0 |
Sequence Alignment | 12 | 0.0 |
Sequence Deletion/genetics | 2 | 1.0 |
Ultraviolet Rays | 8 | 1.0 |
Cardiovascular Diseases/etiology | 4 | 8.0 |
Hyperlipidemia/*complications | 2 | 14.0 |
Cardiovascular Diseases/blood | 4 | 20.0 |
Obesity/blood | 5 | 14.0 |
Retrospective Studies | 4 | 0.0 |
Testosterone/*blood | 4 | 1.0 |
China/epidemiology | 2 | 1.0 |
Genetic Predisposition to Disease | 18 | 0.0 |
Multivariate Analysis | 19 | 1.0 |
China | 3 | 0.0 |
Cholesterol Esters/blood | 11 | 9.0 |
Homocysteine/*blood | 3 | 1.0 |
Progestins/therapeutic use | 2 | 66.0 |
Cholesterol/analysis | 12 | 25.0 |
*Polymorphism, Restriction Fragment Length | 34 | 4.0 |
Apolipoproteins B/blood/*genetics | 31 | 93.0 |
Asian Continental Ancestry Group | 6 | 2.0 |
Cerebral Infarction/*genetics | 2 | 25.0 |
Polymorphism, Restriction Fragment Length | 34 | 1.0 |
Apolipoproteins B/genetics/secretion | 2 | 100.0 |
COS Cells | 12 | 0.0 |
Centrifugation, Density Gradient | 30 | 8.0 |
*Gene Expression | 8 | 0.0 |
Hela Cells | 10 | 0.0 |
Immunosorbent Techniques | 10 | 3.0 |
RNA, Messenger/analysis | 8 | 0.0 |
Aging | 6 | 1.0 |
Apolipoproteins B/blood/genetics | 4 | 66.0 |
Apolipoproteins C/genetics | 7 | 20.0 |
Codon | 6 | 1.0 |
Sex Characteristics | 20 | 3.0 |
Smoking | 7 | 1.0 |
Antibodies, Monoclonal/immunology | 10 | 0.0 |
Chromatography, Gel | 23 | 2.0 |
Macromolecular Substances | 11 | 0.0 |
Macrophages/metabolism | 7 | 2.0 |
Apolipoproteins B/*genetics/metabolism | 12 | 80.0 |
Phylogeny | 11 | 0.0 |
*RNA Editing | 18 | 43.0 |
Recombinant Proteins/genetics/metabolism | 4 | 0.0 |
Cholesterol/*metabolism | 13 | 5.0 |
Lipoproteins, LDL Cholesterol/metabolism | 5 | 14.0 |
Introns/genetics | 2 | 0.0 |
Greece | 3 | 3.0 |
Lipoprotein(a)/blood | 17 | 26.0 |
Postmenopause/*blood | 6 | 12.0 |
Coronary Disease/blood/*etiology | 4 | 50.0 |
Autopsy | 4 | 2.0 |
Endothelium, Vascular/metabolism | 5 | 2.0 |
Immunoenzyme Techniques | 7 | 0.0 |
Lipoprotein(a)/*metabolism | 10 | 83.0 |
Plasminogen/metabolism | 3 | 7.0 |
Obesity/genetics/*metabolism | 2 | 40.0 |
*RNA Processing, Post-Transcriptional | 6 | 10.0 |
Receptors, LDL/genetics/metabolism | 3 | 14.0 |
*Alleles | 23 | 1.0 |
Coronary Disease/blood/*genetics | 9 | 47.0 |
Aorta/*chemistry | 4 | 66.0 |
Apolipoproteins B/analysis/genetics | 3 | 100.0 |
Arteriosclerosis/metabolism | 5 | 8.0 |
Blotting, Southern | 10 | 0.0 |
Liver/chemistry | 3 | 3.0 |
Alcohol Drinking | 6 | 4.0 |
Japan | 11 | 0.0 |
Nephelometry and Turbidimetry/*methods | 3 | 37.0 |
Cattle | 20 | 0.0 |
Cell Nucleus/metabolism | 8 | 0.0 |
Cytoplasm/metabolism | 3 | 0.0 |
RNA Splicing | 5 | 0.0 |
RNA, Messenger/*metabolism | 10 | 1.0 |
Subcellular Fractions/metabolism | 5 | 1.0 |
Transgenes | 5 | 1.0 |
Apoptosis | 3 | 0.0 |
Carrier Proteins/metabolism | 11 | 1.0 |
Lipoproteins/*metabolism | 26 | 16.0 |
Lipoproteins, HDL/metabolism | 11 | 10.0 |
Oxidative Stress | 4 | 1.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/metabolism | 8 | 14.0 |
Fibrinogen/analysis/*genetics | 2 | 50.0 |
*Genetic Markers | 4 | 1.0 |
Arteriosclerosis/*etiology | 5 | 12.0 |
Insulin Resistance/physiology | 5 | 10.0 |
Lipoproteins, LDL Cholesterol/blood/chemistry | 2 | 50.0 |
Liver/physiopathology | 2 | 7.0 |
Coronary Arteriosclerosis/*blood/radiography | 2 | 25.0 |
Dietary Fats/*administration & dosage | 13 | 16.0 |
Postprandial Period | 8 | 8.0 |
Lipoproteins, HDL/blood | 35 | 13.0 |
Half-Life | 6 | 1.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
Rats, Wistar | 4 | 0.0 |
Anthropometry | 16 | 6.0 |
Bezafibrate/*therapeutic use | 3 | 21.0 |
Hyperlipoproteinemia Type IV/blood/drug therapy | 2 | 66.0 |
Hypertriglyceridemia/*blood/*drug therapy | 2 | 100.0 |
Lipoproteins, VLDL/blood | 59 | 26.0 |
Extracellular Matrix/metabolism | 3 | 1.0 |
Glycosaminoglycans/metabolism | 2 | 4.0 |
Heparin/pharmacology | 4 | 1.0 |
Apolipoproteins B/*chemistry/metabolism | 3 | 100.0 |
Computer Simulation | 5 | 1.0 |
Detergents | 4 | 3.0 |
Lipoproteins, LDL/chemistry | 4 | 40.0 |
Protein Structure, Secondary | 5 | 0.0 |
Receptors, LDL/metabolism | 28 | 29.0 |
Structure-Activity Relationship | 23 | 0.0 |
Apolipoproteins/metabolism | 14 | 35.0 |
Down-Regulation | 6 | 0.0 |
Lipoproteins, LDL/pharmacokinetics | 2 | 40.0 |
Oleic Acid/metabolism | 6 | 28.0 |
Apolipoproteins C/*genetics | 18 | 20.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
Apolipoproteins E/*blood/genetics | 2 | 10.0 |
Chromatography, Affinity | 29 | 3.0 |
Hypercholesterolemia/*blood | 5 | 23.0 |
Hypertriglyceridemia/*blood | 7 | 17.0 |
Ultracentrifugation | 37 | 19.0 |
Confidence Intervals | 2 | 0.0 |
Life Style | 6 | 4.0 |
Chromatography, Agarose | 2 | 4.0 |
Lipoproteins, LDL/chemistry/metabolism | 5 | 55.0 |
Mutation | 38 | 0.0 |
Spectrometry, Fluorescence | 10 | 2.0 |
Carrier Proteins/pharmacology | 2 | 3.0 |
Phosphorylation | 3 | 0.0 |
Coronary Disease/*genetics | 13 | 21.0 |
Taiwan | 8 | 4.0 |
Gene Expression Regulation | 25 | 0.0 |
Hyperlipoproteinemia/blood/*etiology/metabolism | 2 | 100.0 |
*African Continental Ancestry Group | 7 | 6.0 |
*European Continental Ancestry Group | 7 | 8.0 |
France | 6 | 2.0 |
Apolipoproteins/*genetics | 14 | 20.0 |
Arteriosclerosis/etiology/*genetics | 2 | 50.0 |
Aspergillus fumigatus/*metabolism | 2 | 50.0 |
Hemolysis/*drug effects | 2 | 5.0 |
Endoplasmic Reticulum/metabolism | 20 | 7.0 |
Phospholipids/pharmacology | 2 | 6.0 |
Apolipoproteins B/chemistry | 5 | 83.0 |
Ascorbic Acid/metabolism | 2 | 16.0 |
Lipid Peroxidation | 7 | 6.0 |
Lipoproteins, LDL/drug effects/*metabolism | 2 | 33.0 |
Disease Models, Animal | 4 | 0.0 |
Hyperlipidemia/genetics | 3 | 18.0 |
Lipoprotein Lipase/genetics | 5 | 16.0 |
C-Peptide/blood | 9 | 5.0 |
Canada | 6 | 4.0 |
Cardiovascular Diseases/blood/*epidemiology | 2 | 40.0 |
*Indians, North American | 2 | 6.0 |
Acetylation | 5 | 0.0 |
CHO Cells | 15 | 0.0 |
Endothelium, Vascular/*metabolism | 4 | 1.0 |
Fibroblasts/*metabolism | 4 | 2.0 |
Hamsters | 22 | 0.0 |
Light | 2 | 0.0 |
Lipoprotein Lipase/*metabolism | 7 | 3.0 |
Lipoproteins, LDL/*pharmacokinetics | 3 | 33.0 |
Scattering, Radiation | 7 | 6.0 |
Up-Regulation | 4 | 0.0 |
Hypertension/genetics | 3 | 13.0 |
Moscow | 3 | 12.0 |
Peptidyl-Dipeptidase A/*genetics | 12 | 3.0 |
DNA Primers/genetics | 8 | 0.0 |
Great Britain | 4 | 1.0 |
Microsomes/metabolism | 10 | 8.0 |
Triglycerides/blood/metabolism | 5 | 22.0 |
*Variation (Genetics) | 24 | 2.0 |
5' Untranslated Regions | 2 | 1.0 |
Apolipoproteins B/*biosynthesis/*genetics | 4 | 100.0 |
Cell Nucleus/chemistry | 2 | 1.0 |
DNA Footprinting | 2 | 0.0 |
Deoxyribonuclease I/metabolism | 3 | 2.0 |
Nucleic Acid Conformation | 6 | 1.0 |
Organ Specificity/genetics | 2 | 1.0 |
Sequence Analysis, DNA | 19 | 0.0 |
Adipose Tissue/*anatomy & histology | 4 | 7.0 |
African Continental Ancestry Group | 2 | 0.0 |
*Body Composition | 6 | 5.0 |
Body Constitution | 8 | 5.0 |
European Continental Ancestry Group | 10 | 1.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Apolipoproteins E/*blood | 15 | 27.0 |
Isoelectric Focusing | 11 | 1.0 |
Spain | 2 | 0.0 |
Apolipoproteins E/blood/*genetics | 8 | 11.0 |
France/ethnology | 2 | 5.0 |
Hypercholesterolemia, Familial/*blood/*genetics | 2 | 50.0 |
Apolipoproteins B/biosynthesis/genetics/*metabolism | 2 | 100.0 |
Bile Acids and Salts/biosynthesis | 3 | 60.0 |
Ubiquitins/metabolism | 4 | 2.0 |
Apolipoproteins B/chemistry/*genetics | 4 | 80.0 |
Base Composition | 4 | 1.0 |
Deoxyribonuclease EcoRI/genetics | 2 | 66.0 |
Enhancer Elements (Genetics) | 4 | 1.0 |
*Enhancer Elements (Genetics) | 4 | 1.0 |
Intestine, Small/*metabolism | 3 | 11.0 |
Mice, Inbred Strains | 7 | 0.0 |
Microinjections | 2 | 0.0 |
*Transgenes | 2 | 4.0 |
Abdomen | 6 | 6.0 |
Biological Markers/analysis | 2 | 0.0 |
Lipoproteins, HDL Cholesterol/*analysis | 2 | 66.0 |
Registries | 5 | 2.0 |
Sampling Studies | 6 | 3.0 |
Fasting/metabolism | 2 | 11.0 |
Forecasting | 4 | 1.0 |
Injections, Intravenous | 4 | 0.0 |
Lasers | 3 | 2.0 |
Lipoproteins, LDL/blood/*chemistry | 3 | 37.0 |
Viscosity | 2 | 6.0 |
Apolipoproteins B/blood/*metabolism | 12 | 85.0 |
Endoplasmic Reticulum, Rough/*metabolism | 2 | 33.0 |
Hyperlipidemia/*metabolism | 6 | 40.0 |
Hypertriglyceridemia/blood | 7 | 29.0 |
Lipoproteins, VLDL/blood/*metabolism | 4 | 40.0 |
Coronary Disease/etiology | 9 | 25.0 |
*Heterozygote | 9 | 2.0 |
*Homozygote | 7 | 4.0 |
Hyperlipidemia/blood/complications/*drug therapy | 2 | 25.0 |
DNA/genetics | 22 | 1.0 |
Genes, Structural/*genetics | 2 | 0.0 |
Tunica Intima/*ultrasonography | 3 | 37.0 |
Tunica Media/*ultrasonography | 3 | 42.0 |
African Continental Ancestry Group/*genetics | 9 | 3.0 |
Coronary Disease/genetics | 6 | 17.0 |
Ethnic Groups/genetics | 2 | 1.0 |
Indians, South American/*genetics | 5 | 7.0 |
Myocardial Infarction/genetics | 3 | 12.0 |
Gene Deletion | 8 | 0.0 |
Peptides/chemistry | 2 | 0.0 |
Triglycerides/*chemistry | 2 | 33.0 |
Apolipoproteins B/*blood/metabolism | 3 | 75.0 |
Linkage (Genetics)/genetics | 4 | 1.0 |
Lod Score | 12 | 1.0 |
*Quantitative Trait, Heritable | 2 | 4.0 |
Variation (Genetics)/genetics | 4 | 2.0 |
Carcinoma, Hepatocellular | 25 | 7.0 |
Carrier Proteins/genetics/*metabolism | 4 | 0.0 |
*Flavanones | 4 | 16.0 |
Flavonoids/*pharmacology | 4 | 5.0 |
*Hesperidin | 2 | 50.0 |
Triglycerides/metabolism | 33 | 20.0 |
Evolution, Molecular | 3 | 0.0 |
Genetic Predisposition to Disease/*genetics | 3 | 0.0 |
Globins/genetics | 3 | 2.0 |
Point Mutation/genetics | 2 | 0.0 |
Cardiovascular Diseases/*epidemiology | 3 | 23.0 |
Glucose Tolerance Test | 13 | 3.0 |
Tunica Intima/*pathology | 2 | 10.0 |
Cardiovascular Diseases/blood/*genetics | 2 | 16.0 |
Italy | 10 | 1.0 |
Renin-Angiotensin System/genetics | 2 | 8.0 |
Carcinoma, Hepatocellular/metabolism | 9 | 9.0 |
Cell-Free System | 6 | 2.0 |
Cytosol/metabolism | 8 | 1.0 |
Glycosylation | 12 | 1.0 |
Liver Neoplasms/metabolism | 7 | 9.0 |
Microsomes, Liver/metabolism | 4 | 2.0 |
Reticulocytes/metabolism | 2 | 2.0 |
Heparin/metabolism | 6 | 4.0 |
Liposomes | 6 | 2.0 |
Skinfold Thickness | 4 | 5.0 |
*Codon, Nonsense | 2 | 3.0 |
Serine Endopeptidases/*genetics | 2 | 3.0 |
Obesity/*blood | 7 | 8.0 |
Food Habits | 3 | 11.0 |
Hypercholesterolemia/blood/*drug therapy | 7 | 28.0 |
Lipid Peroxidation/drug effects | 2 | 3.0 |
Chromatography, Thin Layer | 9 | 5.0 |
Immunoprecipitation | 2 | 0.0 |
Lipoproteins/chemistry | 2 | 16.0 |
Sucrose/pharmacology | 3 | 9.0 |
Triglycerides/chemistry | 2 | 25.0 |
Proteins/*metabolism | 3 | 0.0 |
Ligands | 8 | 0.0 |
Lipolysis | 14 | 16.0 |
Biopsy | 4 | 0.0 |
Genome, Viral | 2 | 1.0 |
Apolipoproteins B/genetics/*metabolism/secretion | 2 | 100.0 |
Cell Fractionation | 2 | 0.0 |
Intracellular Fluid/metabolism | 3 | 2.0 |
RNA, Messenger/analysis/metabolism | 3 | 2.0 |
Menopause | 7 | 3.0 |
Genetic Screening | 7 | 0.0 |
Hypercholesterolemia, Familial/diagnosis/*genetics | 2 | 66.0 |
Molecular Biology | 4 | 1.0 |
Polymorphism, Single-Stranded Conformational | 8 | 0.0 |
Antioxidants | 2 | 6.0 |
Apolipoproteins B/genetics | 23 | 62.0 |
Czech Republic | 2 | 4.0 |
Carotid Arteries/*pathology | 2 | 25.0 |
Biological Availability | 4 | 1.0 |
Macaca fascicularis | 3 | 1.0 |
*Blood Component Removal | 5 | 17.0 |
Fluorescent Antibody Technique | 12 | 0.0 |
Open Reading Frames/genetics | 2 | 1.0 |
RNA, Messenger/genetics/metabolism | 13 | 0.0 |
Apolipoproteins/*chemistry | 2 | 40.0 |
Lipids/chemistry | 4 | 17.0 |
Apolipoproteins/genetics | 4 | 17.0 |
Dietary Fats/metabolism | 3 | 9.0 |
Phospholipases/metabolism | 2 | 11.0 |
Receptors, LDL/physiology | 4 | 22.0 |
Aorta | 6 | 4.0 |
CCAAT-Enhancer-Binding Proteins/*genetics | 2 | 18.0 |
Cardiovascular Diseases/*etiology | 4 | 13.0 |
DNA/*genetics | 11 | 3.0 |
DNA-Binding Proteins/*genetics | 4 | 0.0 |
*Transcription Factors | 5 | 0.0 |
Antibodies, Monoclonal | 27 | 1.0 |
*Coronary Angiography | 3 | 13.0 |
Lipoproteins, HDL Cholesterol/metabolism | 6 | 12.0 |
Statistics | 5 | 1.0 |
Thiobarbituric Acid Reactive Substances/metabolism | 6 | 14.0 |
*Body Weight | 3 | 4.0 |
Insulin Resistance/*physiology | 7 | 9.0 |
Drug Synergism | 2 | 0.0 |
*Transcription, Genetic | 12 | 0.0 |
Ethnic Groups/*genetics | 6 | 3.0 |
*Minisatellite Repeats | 7 | 9.0 |
Variation (Genetics)/*genetics | 9 | 4.0 |
Blood Glucose/*metabolism | 7 | 2.0 |
*Genetic Predisposition to Disease | 5 | 0.0 |
Immunoglobulin G/blood | 3 | 1.0 |
Immunoglobulin M/blood | 2 | 1.0 |
Biological Markers | 7 | 0.0 |
*Multigene Family | 4 | 0.0 |
Apoproteins/metabolism | 2 | 12.0 |
Chylomicrons/*metabolism | 8 | 24.0 |
In Vitro | 29 | 0.0 |
Procetofen/*therapeutic use | 6 | 37.0 |
Triglycerides/analysis/blood | 2 | 40.0 |
Anticholesteremic Agents/*pharmacology | 4 | 13.0 |
Copper/metabolism | 3 | 4.0 |
Fatty Acids, Monounsaturated/*pharmacology | 2 | 22.0 |
Free Radicals | 7 | 4.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology | 6 | 9.0 |
Indoles/*pharmacology | 2 | 2.0 |
Vitamin E/blood | 8 | 18.0 |
Myocardial Infarction/*genetics | 5 | 13.0 |
Lipase/*genetics | 4 | 11.0 |
Lipoproteins, HDL/*blood/classification | 2 | 18.0 |
Liver/*enzymology | 11 | 2.0 |
*Promoter Regions (Genetics) | 9 | 0.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Binding, Competitive/immunology | 2 | 2.0 |
Chemiluminescent Measurements | 2 | 1.0 |
Epitopes/immunology | 7 | 1.0 |
Immunoassay | 13 | 5.0 |
Lipoproteins, LDL/*immunology/metabolism | 2 | 100.0 |
Genes, Recessive | 3 | 0.0 |
Adenoviridae/genetics | 8 | 1.0 |
Apolipoprotein A-I/*secretion | 2 | 100.0 |
Phospholipids/metabolism | 7 | 3.0 |
Combined Modality Therapy | 2 | 0.0 |
Acetylcysteine/*analogs & derivatives/pharmacology | 2 | 4.0 |
Apolipoproteins B/biosynthesis/*metabolism | 5 | 100.0 |
Ubiquitins/*metabolism | 5 | 3.0 |
Glucose Clamp Technique | 3 | 2.0 |
Ascorbic Acid/blood | 3 | 21.0 |
Uric Acid/blood | 3 | 5.0 |
Reference Standards | 8 | 3.0 |
Apolipoproteins E/*deficiency/genetics | 3 | 13.0 |
Chickens | 7 | 0.0 |
Two-Hybrid System Techniques | 3 | 0.0 |
Apolipoproteins E/blood | 18 | 38.0 |
Asian Continental Ancestry Group/genetics | 6 | 1.0 |
Confounding Factors (Epidemiology) | 4 | 6.0 |
*Evolution | 5 | 2.0 |
Gene Frequency/*genetics | 4 | 2.0 |
Mutation/genetics | 5 | 0.0 |
Pilot Projects | 5 | 0.0 |
*Diet | 7 | 3.0 |
Lipids/*blood/metabolism | 2 | 16.0 |
*Neoplasm Proteins | 5 | 0.0 |
*Tumor Suppressor Proteins | 5 | 0.0 |
Apolipoproteins A/blood/*genetics | 3 | 25.0 |
Coronary Disease/blood/genetics | 3 | 27.0 |
Family | 4 | 1.0 |
Lipase/*metabolism | 3 | 5.0 |
Apolipoproteins B/*chemistry | 10 | 100.0 |
Dietary Fats/pharmacology | 4 | 11.0 |
Fatty Acids/*pharmacology | 4 | 15.0 |
Apolipoprotein A-I/*biosynthesis/genetics/secretion | 2 | 66.0 |
Apolipoproteins B/*biosynthesis/genetics/secretion | 3 | 100.0 |
Dithiothreitol/pharmacology | 8 | 8.0 |
Hydroxymethylglutaryl CoA Reductases/metabolism | 5 | 27.0 |
Liver/*drug effects/metabolism/secretion | 2 | 100.0 |
Lipase/blood | 7 | 9.0 |
Leptin/*blood | 2 | 2.0 |
Radioimmunoassay | 18 | 0.0 |
Diabetes Mellitus, Type 2/*blood | 7 | 5.0 |
Liver/drug effects/metabolism | 2 | 2.0 |
Mice, Mutant Strains | 4 | 0.0 |
Polymerase Chain Reaction/methods | 9 | 0.0 |
Tandem Repeat Sequences | 2 | 1.0 |
*Bone Marrow Transplantation | 3 | 0.0 |
DNA/*analysis | 8 | 3.0 |
Polymerase Chain Reaction/*methods | 10 | 1.0 |
Silver Staining | 3 | 3.0 |
Transplantation Chimera/*genetics | 2 | 40.0 |
Electron Spin Resonance Spectroscopy | 4 | 1.0 |
Spin Labels | 4 | 3.0 |
Binding, Competitive | 32 | 1.0 |
Copper/*chemistry | 3 | 27.0 |
Thyrotropin/blood | 4 | 1.0 |
Triiodothyronine/blood | 2 | 0.0 |
RNA Editing | 7 | 38.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | 4 | 12.0 |
Leucine | 3 | 6.0 |
Nuclear Family | 5 | 2.0 |
DNA Primers/chemistry | 4 | 0.0 |
Lipoproteins/analysis | 3 | 13.0 |
Abetalipoproteinemia/blood/*genetics | 3 | 100.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
Lipid Peroxides/blood | 3 | 12.0 |
Cryoelectron Microscopy | 2 | 12.0 |
Deoxycholic Acid | 4 | 50.0 |
Ice | 3 | 75.0 |
Lipoproteins, LDL/blood/chemistry | 2 | 50.0 |
Antibodies, Monoclonal/pharmacology | 3 | 0.0 |
Lipoproteins, LDL/blood/*metabolism | 5 | 33.0 |
Receptors, Immunologic/*metabolism | 3 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Esterification | 8 | 9.0 |
Lipoproteins/*blood/chemistry | 4 | 33.0 |
Carbon Isotopes | 5 | 9.0 |
Diabetes Mellitus, Type 2/blood/*metabolism | 2 | 22.0 |
Insulin/pharmacology | 2 | 0.0 |
Leucine/metabolism | 6 | 9.0 |
Lipoproteins, VLDL/blood/metabolism | 4 | 44.0 |
Chemistry, Physical | 5 | 3.0 |
Hypercholesterolemia, Familial/*genetics | 7 | 15.0 |
Linkage (Genetics) | 24 | 0.0 |
Lipoproteins, LDL Cholesterol/analysis | 2 | 40.0 |
Triglycerides/analysis | 13 | 39.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 5 | 4.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/blood | 4 | 5.0 |
Apolipoprotein A-II/*genetics | 4 | 40.0 |
Arteriosclerosis/genetics | 4 | 13.0 |
Fatty Acids, Nonesterified/blood | 13 | 6.0 |
Hyperlipidemia, Familial Combined/*genetics | 3 | 25.0 |
Abetalipoproteinemia/*genetics | 3 | 42.0 |
Frameshift Mutation | 3 | 0.0 |
*Diet, Reducing | 3 | 4.0 |
Fibrinogen/metabolism | 3 | 1.0 |
Hematocrit | 2 | 0.0 |
Obesity/*blood/physiopathology | 2 | 16.0 |
Weight Loss | 4 | 2.0 |
Lipoproteins/*blood/drug effects | 2 | 20.0 |
Lipoproteins, LDL/blood/drug effects | 2 | 40.0 |
Placebos | 10 | 4.0 |
*Gene Expression Regulation | 16 | 0.0 |
Transcription, Genetic | 24 | 0.0 |
Apolipoproteins B/chemistry/*genetics/metabolism | 3 | 100.0 |
Intestine, Small/metabolism | 5 | 9.0 |
RNA Processing, Post-Transcriptional | 6 | 5.0 |
DNA/blood | 3 | 1.0 |
Genome, Human | 2 | 0.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 2 | 2.0 |
Lipoproteins, LDL/*chemistry | 13 | 61.0 |
Models, Chemical | 3 | 0.0 |
*Diet, Fat-Restricted | 2 | 10.0 |
Finland | 7 | 2.0 |
Enzyme-Linked Immunosorbent Assay/methods | 6 | 2.0 |
Molecular Weight | 44 | 1.0 |
Hyperlipidemia, Familial Combined/*blood/*genetics | 3 | 75.0 |
Cysteine Endopeptidases/*metabolism | 12 | 5.0 |
Cytosol/*metabolism | 2 | 6.0 |
Endopeptidase K/metabolism | 2 | 13.0 |
Multienzyme Complexes/*metabolism | 9 | 6.0 |
Hypercholesterolemia, Familial/*blood/complications | 2 | 66.0 |
Latex Fixation Tests | 2 | 7.0 |
Apolipoproteins E/*analysis | 4 | 16.0 |
Blood Platelets/drug effects/*physiology | 2 | 4.0 |
Gemfibrozil/pharmacology | 3 | 75.0 |
Hyperlipoproteinemia Type IV/*blood | 4 | 33.0 |
Lipoproteins, VLDL/*analysis | 3 | 60.0 |
Receptors, LDL/analysis | 4 | 36.0 |
Apolipoproteins B/chemistry/metabolism | 4 | 80.0 |
Arginine/chemistry | 3 | 4.0 |
Chromatography, Ion Exchange | 4 | 1.0 |
Fibroblasts/metabolism | 28 | 3.0 |
Iodine Radioisotopes | 15 | 4.0 |
Receptors, Cell Surface/metabolism | 7 | 1.0 |
Receptors, LDL/*metabolism | 24 | 26.0 |
Lipoproteins/analysis/*blood | 2 | 50.0 |
Peritoneal Dialysis/*adverse effects | 3 | 20.0 |
Animals, Genetically Modified | 5 | 2.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Phosphatidylcholines | 2 | 5.0 |
Staining and Labeling | 4 | 0.0 |
Arteriosclerosis/*metabolism | 9 | 13.0 |
Freezing | 5 | 5.0 |
Coronary Disease/*metabolism | 3 | 30.0 |
Lipoproteins, LDL/*chemistry/*metabolism | 2 | 100.0 |
Arteriosclerosis/etiology | 6 | 8.0 |
Chylomicrons/*blood | 2 | 6.0 |
Dietary Fats | 3 | 7.0 |
Insulin/*pharmacology | 6 | 2.0 |
Multigene Family | 3 | 0.0 |
Coronary Disease/*blood/etiology | 4 | 44.0 |
Odds Ratio | 8 | 0.0 |
Cell Line, Tumor | 8 | 0.0 |
Mutagenesis | 5 | 0.0 |
Oleic Acid/metabolism/pharmacology | 3 | 100.0 |
Protein Structure, Quaternary | 2 | 1.0 |
Tritium/diagnostic use | 2 | 1.0 |
C-Reactive Protein/*metabolism | 2 | 0.0 |
Fatty Acids, Omega-3/*therapeutic use | 2 | 20.0 |
Simvastatin/*therapeutic use | 2 | 8.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
Deoxyribonuclease EcoRI/metabolism | 2 | 12.0 |
Nuclear Proteins/metabolism | 4 | 0.0 |
Ribonucleases/metabolism | 2 | 1.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Cysteine | 2 | 1.0 |
Hydrocortisone/blood | 3 | 0.0 |
Syndrome | 5 | 0.0 |
Autoantibodies/blood/immunology | 2 | 10.0 |
Molecular Structure | 11 | 1.0 |
Stereoisomerism | 5 | 1.0 |
Lysine/analogs & derivatives/pharmacology | 2 | 40.0 |
Forensic Medicine/*methods | 2 | 6.0 |
Minisatellite Repeats | 5 | 3.0 |
Apolipoprotein A-I/*biosynthesis/genetics | 3 | 50.0 |
Lipoproteins, HDL/*blood | 27 | 13.0 |
Liver/cytology/drug effects/*metabolism | 2 | 10.0 |
Homeostasis | 4 | 1.0 |
Apolipoprotein A-I/*metabolism | 7 | 16.0 |
Apolipoproteins B/*blood/*genetics | 9 | 100.0 |
Deuterium | 3 | 10.0 |
Hypercholesterolemia, Familial/blood/*genetics | 3 | 30.0 |
Leucine/blood/diagnostic use | 2 | 66.0 |
Epitope Mapping | 3 | 1.0 |
Epitopes/blood | 2 | 25.0 |
*Protein Conformation | 4 | 1.0 |
*Adipose Tissue | 4 | 11.0 |
*Anthropometry | 3 | 9.0 |
Injections, Subcutaneous | 2 | 0.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
Hepatoblastoma/*metabolism/pathology | 3 | 60.0 |
Hepatocyte Growth Factor/pharmacology | 2 | 3.0 |
Liver Neoplasms/metabolism/pathology | 2 | 12.0 |
Transforming Growth Factor alpha/pharmacology | 2 | 2.0 |
Transforming Growth Factor beta/*pharmacology | 2 | 0.0 |
Apolipoproteins B/chemistry/*metabolism | 7 | 100.0 |
Macrophages, Peritoneal/metabolism | 2 | 8.0 |
Cytidine Deaminase/metabolism | 3 | 27.0 |
Body Height | 3 | 1.0 |
Random Allocation | 5 | 1.0 |
Binding Sites/drug effects | 2 | 3.0 |
Indoles/pharmacology | 2 | 0.0 |
Piperidines/pharmacology | 2 | 3.0 |
Protein Binding/drug effects | 4 | 1.0 |
Apolipoproteins E/blood/genetics | 6 | 37.0 |
Estradiol/blood | 5 | 0.0 |
Hysterectomy | 2 | 2.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Mass Fragmentography | 10 | 4.0 |
*Gene Rearrangement | 2 | 0.0 |
China/ethnology | 4 | 2.0 |
India/ethnology | 3 | 4.0 |
Singapore | 4 | 8.0 |
Cell Membrane/metabolism | 5 | 0.0 |
Triglycerides/secretion | 8 | 72.0 |
Minisatellite Repeats/genetics | 2 | 4.0 |
Apolipoproteins B/blood/*secretion | 3 | 100.0 |
Liver/secretion | 2 | 50.0 |
*Hemostasis | 2 | 1.0 |
Apolipoproteins B/*chemistry/genetics/*metabolism/secretion | 2 | 100.0 |
Cholesterol Esters/*metabolism | 10 | 11.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Golgi Apparatus/metabolism | 4 | 2.0 |
Lipids/analysis | 8 | 17.0 |
*Protein Processing, Post-Translational | 5 | 1.0 |
Apolipoproteins E/*metabolism | 8 | 7.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Protein Folding | 6 | 1.0 |
Temperature | 8 | 0.0 |
Apolipoproteins B/genetics/*secretion | 7 | 100.0 |
Genetic Vectors | 6 | 0.0 |
Liver/cytology/*metabolism | 8 | 10.0 |
Receptors, LDL/genetics/*metabolism | 4 | 15.0 |
Peritoneal Dialysis | 2 | 5.0 |
Lipoproteins/blood/metabolism | 6 | 35.0 |
*Lipolysis | 3 | 10.0 |
Lipoproteins, HDL/*metabolism | 6 | 5.0 |
Adipose Tissue/anatomy & histology | 2 | 7.0 |
Lipoprotein Lipase/*blood | 3 | 2.0 |
Membrane Proteins/*blood | 2 | 3.0 |
Adipose Tissue/*metabolism | 4 | 3.0 |
CCAAT-Enhancer-Binding Proteins | 4 | 2.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Hypoglycemic Agents/*therapeutic use | 2 | 3.0 |
Insulin/*therapeutic use | 3 | 3.0 |
Lipoproteins/blood/*metabolism | 8 | 25.0 |
Software | 2 | 0.0 |
Acute Disease | 3 | 0.0 |
Lovastatin/*therapeutic use | 5 | 50.0 |
Trypsin | 3 | 1.0 |
Cross-Over Studies | 18 | 2.0 |
Drug Combinations | 7 | 1.0 |
Hyperlipidemia, Familial Combined/*blood/*drug therapy | 2 | 66.0 |
Lipoproteins, LDL/*blood/classification | 3 | 50.0 |
Cardiovascular Diseases/genetics | 3 | 11.0 |
Lipoproteins/*blood/classification | 3 | 75.0 |
Diet Surveys | 2 | 8.0 |
United States | 8 | 0.0 |
Isotope Labeling/methods | 2 | 8.0 |
Metabolic Syndrome X/*blood | 3 | 27.0 |
Circular Dichroism | 9 | 2.0 |
Amino Acids/analysis | 11 | 4.0 |
Dose-Response Relationship, Radiation | 2 | 0.0 |
Amidines/pharmacology | 2 | 15.0 |
Apolipoproteins B/*blood/chemistry | 2 | 100.0 |
Copper/pharmacology | 6 | 11.0 |
Serum Albumin/analysis | 4 | 2.0 |
Electrophoresis, Capillary/*methods | 3 | 9.0 |
3T3 Cells | 2 | 0.0 |
Fatty Acids | 2 | 20.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Liver/*secretion | 6 | 75.0 |
Species Specificity | 19 | 0.0 |
Menopause/blood | 3 | 16.0 |
Sex Hormone-Binding Globulin/analysis | 2 | 0.0 |
Testosterone/blood | 3 | 0.0 |
Protein Sorting Signals/*genetics | 7 | 20.0 |
Coronary Disease/epidemiology/*genetics | 2 | 15.0 |
Italy/epidemiology | 3 | 1.0 |
Endopeptidases/metabolism | 5 | 3.0 |
Recombinant Proteins | 3 | 0.0 |
Crosses, Genetic | 2 | 0.0 |
Glycerol/metabolism | 3 | 7.0 |
Lipoproteins, VLDL/*metabolism | 17 | 24.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
*Phytosterols | 3 | 60.0 |
Triglycerides/blood/*metabolism | 2 | 11.0 |
Tritium | 10 | 4.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
Mexican Americans | 2 | 20.0 |
*Models, Biological | 3 | 1.0 |
Obesity/*blood/*genetics | 2 | 40.0 |
Hydrocortisone/*blood | 2 | 1.0 |
Dietary Carbohydrates/*administration & dosage | 3 | 12.0 |
Dietary Fats, Unsaturated/*administration & dosage | 2 | 10.0 |
Anticoagulants/*therapeutic use | 3 | 6.0 |
*Coronary Artery Bypass | 2 | 2.0 |
Dietary Fats/*pharmacology | 10 | 15.0 |
Fish Oils/*pharmacology | 3 | 30.0 |
Calcium-Binding Proteins/*metabolism | 2 | 2.0 |
Glucose/*metabolism | 3 | 1.0 |
Molecular Chaperones/*metabolism | 4 | 7.0 |
Dietary Fats/*metabolism | 4 | 17.0 |
Liver/metabolism/secretion | 3 | 100.0 |
Matched-Pair Analysis | 4 | 4.0 |
Organ Specificity | 8 | 0.0 |
Premenopause/*blood | 2 | 11.0 |
Hypertension/blood/*drug therapy/physiopathology | 2 | 12.0 |
Carotid Artery Diseases/*epidemiology/etiology/ultrasonography | 2 | 100.0 |
Disease Susceptibility | 5 | 0.0 |
Finland/epidemiology | 3 | 2.0 |
Carrier Proteins/antagonists & inhibitors/*metabolism | 2 | 16.0 |
Liver Neoplasms, Experimental | 5 | 10.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Immunoassay/methods | 2 | 3.0 |
Infant, Newborn | 11 | 0.0 |
Cholesterol Esters/biosynthesis | 5 | 35.0 |
Hemoglobin A, Glycosylated/analysis | 11 | 2.0 |
Malondialdehyde/blood | 3 | 4.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Oligodeoxyribonucleotides/chemistry | 2 | 0.0 |
Peptide Fragments/chemistry | 3 | 1.0 |
Evaluation Studies | 6 | 0.0 |
Paternity | 2 | 2.0 |
Single-Blind Method | 2 | 0.0 |
Specimen Handling | 3 | 3.0 |
Age of Onset | 2 | 0.0 |
*Genes, Structural | 9 | 1.0 |
Protein Biosynthesis | 6 | 0.0 |
*RNA Splicing | 3 | 1.0 |
RNA, Messenger/analysis/*metabolism | 2 | 6.0 |
Endarterectomy, Carotid | 3 | 23.0 |
Extracellular Matrix Proteins/metabolism | 2 | 2.0 |
Obesity/*metabolism | 2 | 2.0 |
Carrier Proteins/antagonists & inhibitors | 2 | 25.0 |
Apolipoproteins B/*chemistry/*metabolism | 4 | 100.0 |
Lipoproteins/chemistry/*metabolism | 3 | 23.0 |
Germany | 7 | 2.0 |
Obesity | 3 | 5.0 |
Turkey | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel/*methods | 3 | 10.0 |
Hydrogen-Ion Concentration | 6 | 0.0 |
Blood Pressure/drug effects | 2 | 0.0 |
Fatty Acids/blood | 4 | 8.0 |
Blood Coagulation Factors/analysis | 2 | 3.0 |
Triglycerides/blood/chemistry | 2 | 28.0 |
Chronic Disease | 3 | 0.0 |
Phospholipids/blood | 14 | 10.0 |
Proteinuria/urine | 2 | 12.0 |
Anticholesteremic Agents/*administration & dosage/adverse effects | 2 | 50.0 |
Diet, Fat-Restricted | 3 | 15.0 |
Drug Administration Schedule | 2 | 0.0 |
Apolipoproteins B/blood/isolation & purification | 3 | 60.0 |
Chemical Fractionation | 6 | 8.0 |
Plasma/chemistry | 2 | 6.0 |
Antioxidants/metabolism | 3 | 3.0 |
Blood Donors | 2 | 0.0 |
Electrochemistry | 4 | 4.0 |
*Epitopes | 2 | 1.0 |
Lipoproteins, LDL/*immunology | 6 | 46.0 |
London/epidemiology | 2 | 6.0 |
Fatty Acids/pharmacology | 4 | 23.0 |
Taurocholic Acid/pharmacology | 3 | 33.0 |
*Genetics, Population | 10 | 2.0 |
Anticholesteremic Agents/*administration & dosage | 2 | 20.0 |
Apolipoproteins B/*drug effects/metabolism | 2 | 100.0 |
Lipoproteins, LDL/*drug effects/metabolism | 2 | 100.0 |
Conserved Sequence | 3 | 0.0 |
*Evolution, Molecular | 3 | 0.0 |
Immune Sera/immunology | 2 | 1.0 |
Eating/*physiology | 2 | 2.0 |
Fasting | 13 | 4.0 |
Creatinine/blood | 6 | 1.0 |
Nephrotic Syndrome/*blood | 3 | 20.0 |
Serum Albumin/*metabolism | 2 | 4.0 |
Apolipoproteins A/genetics | 9 | 56.0 |
Emulsions | 7 | 10.0 |
Substrate Specificity | 5 | 0.0 |
Apolipoproteins C/blood | 13 | 44.0 |
Postmortem Changes | 2 | 2.0 |
Factor VIIa/metabolism | 2 | 4.0 |
Recurrence | 2 | 0.0 |
Blood Protein Electrophoresis | 6 | 5.0 |
Chylomicrons/blood | 3 | 7.0 |
Comorbidity | 3 | 1.0 |
Coronary Disease/blood/*epidemiology/genetics | 2 | 40.0 |
Eating | 2 | 1.0 |
European Continental Ancestry Group/*genetics | 5 | 1.0 |
Apolipoproteins B/analysis | 13 | 46.0 |
Lipoproteins, LDL/*analysis | 9 | 69.0 |
Iodine Radioisotopes/diagnostic use | 7 | 2.0 |
Hypobetalipoproteinemia/blood/*genetics | 7 | 100.0 |
Gene Targeting | 2 | 0.0 |
Hypobetalipoproteinemia/genetics/metabolism | 2 | 100.0 |
*Chromosome Mapping | 7 | 0.0 |
Lipoproteins, LDL Cholesterol | 6 | 24.0 |
Glycoproteins/*blood | 3 | 4.0 |
Hyperlipidemia/blood/*etiology | 2 | 40.0 |
Serum Albumin/metabolism | 2 | 1.0 |
Netherlands/epidemiology | 2 | 1.0 |
Acetates/metabolism | 4 | 30.0 |
Drug Interactions | 2 | 0.0 |
Hydroxycholesterols/pharmacology | 3 | 10.0 |
Triglycerides/biosynthesis | 6 | 46.0 |
Cholesterol/*biosynthesis | 3 | 16.0 |
Cholesterol, Dietary/*administration & dosage | 5 | 45.0 |
Energy Intake | 4 | 2.0 |
Human Growth Hormone/*deficiency/*therapeutic use | 2 | 20.0 |
Immunoelectrophoresis, Two-Dimensional | 3 | 2.0 |
Infusions, Intravenous | 2 | 0.0 |
Apolipoproteins B/*antagonists & inhibitors/metabolism/*secretion | 2 | 100.0 |
Carbon Radioisotopes | 4 | 4.0 |
Apolipoproteins B/genetics/*metabolism | 9 | 81.0 |
Endoplasmic Reticulum | 2 | 40.0 |
Liver/enzymology | 12 | 2.0 |
Apolipoproteins A/*analysis | 5 | 50.0 |
Lipoprotein(a)/analysis | 3 | 37.0 |
Mutation/physiology | 2 | 1.0 |
Phosphatidylcholines/*metabolism | 3 | 6.0 |
Chromans/*pharmacology | 3 | 11.0 |
Sulfur Radioisotopes/diagnostic use | 2 | 7.0 |
Vitamin E/*analogs & derivatives/pharmacology | 2 | 50.0 |
Cell Compartmentation | 4 | 1.0 |
Cell Membrane/metabolism/ultrastructure | 2 | 3.0 |
LDL-Receptor Related Protein 1 | 6 | 5.0 |
*Liposomes | 3 | 8.0 |
Macrophages/*metabolism/ultrastructure | 3 | 50.0 |
*Membrane Proteins | 5 | 0.0 |
*Receptors, Lipoprotein | 9 | 6.0 |
Tyrosine/metabolism | 2 | 0.0 |
Arteriosclerosis/*genetics | 2 | 7.0 |
Lipase/metabolism | 7 | 13.0 |
Lipoproteins, VLDL/*biosynthesis | 3 | 50.0 |
*Protein Biosynthesis | 8 | 1.0 |
Hypobetalipoproteinemia/genetics | 3 | 75.0 |
Lipoproteins/secretion | 2 | 66.0 |
Myocardium/metabolism | 3 | 1.0 |
Forensic Medicine | 2 | 3.0 |
Lipoprotein Lipase/metabolism | 9 | 8.0 |
Apolipoproteins B/*antagonists & inhibitors | 2 | 66.0 |
Smoking/adverse effects | 5 | 1.0 |
Chloramphenicol O-Acetyltransferase/genetics | 3 | 1.0 |
Genes, Reporter | 5 | 0.0 |
*Point Mutation | 7 | 0.0 |
Dimerization | 3 | 0.0 |
Escherichia coli/*genetics | 2 | 2.0 |
Recombinant Proteins/administration & dosage | 2 | 2.0 |
Electrophoresis, Polyacrylamide Gel/methods | 5 | 4.0 |
Aorta/metabolism | 4 | 10.0 |
Swine | 10 | 0.0 |
Carrier Proteins/analysis | 2 | 2.0 |
Hyperlipoproteinemia/*blood | 2 | 8.0 |
*Hormone Replacement Therapy | 2 | 5.0 |
Mevalonic Acid/blood | 2 | 100.0 |
Drosophila melanogaster | 4 | 3.0 |
Aging/blood | 5 | 9.0 |
Apolipoproteins B/*chemistry/genetics/metabolism | 2 | 100.0 |
*Models, Molecular | 2 | 1.0 |
Apolipoprotein A-I/analysis | 4 | 21.0 |
Fish Oils/*administration & dosage | 3 | 30.0 |
Plant Oils/*administration & dosage | 2 | 33.0 |
Deoxyribonucleases, Type II Site-Specific | 10 | 3.0 |
Lipoproteins/*blood/metabolism | 2 | 15.0 |
Lipoproteins, LDL/blood/metabolism | 2 | 20.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Myocardial Infarction/blood/*genetics | 5 | 38.0 |
Apolipoproteins B/immunology/*metabolism | 6 | 100.0 |
Peptide Fragments/metabolism | 6 | 1.0 |
Apolipoproteins B/chemistry/genetics/*metabolism | 4 | 100.0 |
Exercise | 3 | 2.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Trypsin/pharmacology | 3 | 2.0 |
Lipoproteins/*genetics | 2 | 5.0 |
Inhibitory Concentration 50 | 2 | 0.0 |
Internet | 3 | 3.0 |
Lipoproteins/*analysis/metabolism | 3 | 100.0 |
Proteinuria/metabolism | 2 | 14.0 |
Oligodeoxyribonucleotides/genetics | 2 | 2.0 |
Hyperlipidemia, Familial Combined/blood/*drug therapy | 3 | 75.0 |
Apolipoprotein A-I/*genetics | 6 | 20.0 |
Apolipoproteins A/*genetics | 9 | 19.0 |
Culture Media, Conditioned | 2 | 0.0 |
Liver/drug effects/*metabolism | 9 | 12.0 |
Linkage Disequilibrium/*genetics | 2 | 2.0 |
Arteriosclerosis/blood/etiology | 7 | 50.0 |
Genetic Vectors/genetics | 3 | 1.0 |
Regulatory Sequences, Nucleic Acid | 7 | 1.0 |
Kringles/physiology | 2 | 100.0 |
Membrane Proteins/metabolism | 3 | 0.0 |
Plant Oils/*pharmacology | 2 | 50.0 |
Liver/cytology | 2 | 3.0 |
Apolipoproteins A/metabolism | 5 | 29.0 |
Hypercholesterolemia, Familial/*metabolism | 4 | 66.0 |
Hyperlipoproteinemia/*metabolism | 3 | 37.0 |
Lipoproteins, VLDL/*secretion | 3 | 50.0 |
Obesity/*physiopathology | 3 | 5.0 |
Acetylcysteine/analogs & derivatives/pharmacology | 2 | 9.0 |
Liver Neoplasms | 21 | 7.0 |
Quinones/pharmacology | 2 | 1.0 |
Exertion | 4 | 5.0 |
Culture Media, Conditioned/pharmacology | 3 | 1.0 |
Gene Transfer Techniques | 7 | 1.0 |
*Lipoprotein(a) | 8 | 66.0 |
Plasmids | 15 | 1.0 |
Coronary Arteriosclerosis/*metabolism/pathology | 2 | 33.0 |
Ascorbic Acid/*pharmacology | 3 | 9.0 |
Lipoproteins, LDL/chemistry/*metabolism | 2 | 15.0 |
Thiobarbituric Acid Reactive Substances/analysis | 2 | 9.0 |
DNA Restriction Enzymes/metabolism | 2 | 2.0 |
Electrocardiography | 2 | 0.0 |
Cholesterol/*biosynthesis/*blood | 2 | 66.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Lipoproteins, LDL/*pharmacology | 4 | 6.0 |
Protein Binding/physiology | 2 | 0.0 |
Protein Denaturation | 6 | 2.0 |
Cysteine/metabolism | 2 | 2.0 |
Sulfur Radioisotopes | 6 | 8.0 |
Genes, Dominant | 3 | 0.0 |
Hyperlipidemia, Familial Combined/blood/*genetics | 2 | 50.0 |
Likelihood Functions | 4 | 2.0 |
Models, Statistical | 5 | 2.0 |
Gene Dosage | 2 | 0.0 |
Histocytochemistry | 2 | 0.0 |
Hyperlipidemia/blood/*drug therapy | 7 | 30.0 |
Lipoproteins, LDL/*blood/drug effects | 2 | 40.0 |
Liver Function Tests | 2 | 1.0 |
*Breast Feeding | 2 | 3.0 |
C-Reactive Protein/analysis | 2 | 0.0 |
Infant Nutrition | 2 | 9.0 |
Arteriosclerosis/blood/*etiology | 2 | 33.0 |
Intracellular Membranes/*metabolism | 3 | 4.0 |
Recombinant Fusion Proteins/biosynthesis | 3 | 0.0 |
Apolipoproteins B/biosynthesis | 5 | 55.0 |
Cell Survival/drug effects | 6 | 0.0 |
Glycosylation End Products, Advanced/*metabolism | 3 | 7.0 |
Receptors, LDL/immunology/*metabolism | 3 | 42.0 |
Antibodies/metabolism | 2 | 2.0 |
Monocytes/*metabolism | 3 | 0.0 |
Hypercholesterolemia, Familial/blood/complications/*genetics | 2 | 66.0 |
Antibodies/immunology | 4 | 1.0 |
Membrane Proteins/*metabolism | 3 | 0.0 |
*Body Constitution | 2 | 7.0 |
Genetic Techniques | 2 | 2.0 |
Indicators and Reagents | 2 | 0.0 |
RNA, Messenger/genetics/*metabolism | 5 | 4.0 |
Extracellular Space/metabolism | 2 | 3.0 |
Muscle, Smooth, Vascular/metabolism/pathology | 2 | 11.0 |
Apolipoproteins B/*biosynthesis/genetics | 6 | 100.0 |
Cytidine Deaminase/biosynthesis/*metabolism | 2 | 100.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Chi-Square Distribution | 4 | 0.0 |
Cholesterol/biosynthesis/secretion | 2 | 50.0 |
Heptanoic Acids/*pharmacology | 3 | 14.0 |
Pyrroles/*pharmacology | 3 | 6.0 |
Lipoproteins | 2 | 33.0 |
RNA, Messenger | 2 | 0.0 |
Receptors, LDL/*genetics/metabolism | 5 | 17.0 |
Energy Intake/physiology | 2 | 7.0 |
Cholesterol Esters/chemistry | 2 | 40.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 3 | 2.0 |
*Transfection | 4 | 1.0 |
Animal Feed | 2 | 11.0 |
Apolipoproteins B/*biosynthesis/blood/genetics | 2 | 100.0 |
Guinea Pigs | 2 | 0.0 |
Models, Theoretical | 2 | 1.0 |
Receptors, LDL/drug effects/*metabolism | 2 | 66.0 |
*Introns | 3 | 1.0 |
*Polymerase Chain Reaction | 3 | 1.0 |
*Computer Simulation | 2 | 2.0 |
Lipase/*blood | 2 | 3.0 |
Menopause/*blood | 4 | 16.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*blood | 2 | 1.0 |
Postmenopause/blood | 3 | 10.0 |
Premenopause/blood | 2 | 11.0 |
Apolipoproteins B/*chemistry/genetics | 4 | 100.0 |
Apolipoproteins B/blood/*genetics/metabolism | 3 | 100.0 |
DNA | 8 | 0.0 |
Diabetes Mellitus, Type 2/*genetics | 3 | 1.0 |
Chromosomes, Human, Pair 1/genetics | 2 | 1.0 |
Hyperlipidemia/*genetics | 5 | 22.0 |
Mice, Inbred C3H | 2 | 0.0 |
Chromosomes, Artificial, Yeast | 3 | 0.0 |
Deoxyribonuclease EcoRI | 5 | 10.0 |
Deoxyribonuclease HindIII | 2 | 4.0 |
Electrophoresis | 5 | 1.0 |
Oligonucleotide Probes | 10 | 1.0 |
Regulatory Sequences, Nucleic Acid/*genetics | 2 | 2.0 |
Transplantation, Homologous | 3 | 0.0 |
Ovariectomy | 3 | 2.0 |
Thyroxine/*therapeutic use | 2 | 11.0 |
Histidine/metabolism | 2 | 10.0 |
Twins, Monozygotic | 4 | 5.0 |
Apolipoproteins A/*metabolism | 3 | 37.0 |
Lipoprotein(a)/*biosynthesis | 2 | 100.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
*Linkage (Genetics) | 4 | 0.0 |
Carrier Proteins/blood/*genetics | 2 | 6.0 |
*Exons | 3 | 0.0 |
Hypercholesterolemia/genetics | 4 | 50.0 |
Biological Transport, Active | 6 | 3.0 |
Fluorescence | 4 | 1.0 |
*Repetitive Sequences, Nucleic Acid | 6 | 1.0 |
Follicle Stimulating Hormone/blood | 2 | 0.0 |
Horses | 2 | 1.0 |
Lipoproteins, LDL/blood/genetics | 2 | 40.0 |
Lipoprotein Lipase/*genetics | 7 | 3.0 |
Gestational Age | 3 | 0.0 |
Fatty Acids/*metabolism | 5 | 5.0 |
Microsomes/*chemistry | 2 | 100.0 |
Cycloheximide/pharmacology | 4 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 5 | 1.0 |
Antilipemic Agents/*pharmacology | 6 | 16.0 |
Apolipoproteins C/blood/genetics | 2 | 50.0 |
Iron/blood | 2 | 2.0 |
Apolipoproteins/*genetics/metabolism | 2 | 50.0 |
Sterol O-Acyltransferase/metabolism | 4 | 21.0 |
Kidney Failure, Chronic/*complications | 2 | 5.0 |
Carbohydrate Sequence | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/metabolism | 2 | 1.0 |
Lectins/metabolism | 2 | 2.0 |
Plasmids/metabolism | 2 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Antilipemic Agents/*administration & dosage | 2 | 14.0 |
Aorta/*metabolism | 2 | 18.0 |
Protease Inhibitors/pharmacology | 7 | 3.0 |
Apoproteins/blood | 6 | 31.0 |
*Lipid Peroxidation | 4 | 8.0 |
Arteriosclerosis/*pathology | 2 | 7.0 |
Rural Population | 2 | 2.0 |
Obesity/blood/*complications | 2 | 25.0 |
Plasminogen Activator Inhibitor 1/*blood | 2 | 6.0 |
Smoking/blood | 4 | 9.0 |
Carcinoma, Hepatocellular/metabolism/pathology/secretion | 2 | 66.0 |
Docosahexaenoic Acids/*pharmacology | 2 | 16.0 |
Fatty Acids/metabolism | 3 | 2.0 |
Liver Neoplasms/metabolism/pathology/secretion | 2 | 50.0 |
Lipoproteins, HDL/chemistry/metabolism | 2 | 33.0 |
Tunicamycin/pharmacology | 3 | 3.0 |
Cell Differentiation | 2 | 0.0 |
Recombinant Fusion Proteins/physiology | 3 | 1.0 |
Triazenes/pharmacology | 2 | 33.0 |
Neuraminidase/pharmacology | 2 | 2.0 |
Hypercholesterolemia/blood | 6 | 31.0 |
Genes, Regulator | 4 | 3.0 |
Lipoproteins, LDL/*blood/metabolism | 3 | 75.0 |
Cholesterol Esters/analysis | 7 | 77.0 |
Estrogens/blood | 2 | 4.0 |
Receptors, Immunologic/metabolism | 3 | 1.0 |
Cercopithecus aethiops | 5 | 0.0 |
Apolipoproteins B/blood/metabolism | 4 | 57.0 |
Chromatography, Liquid | 2 | 1.0 |
Fibroblasts | 2 | 0.0 |
Proteoglycans/metabolism | 2 | 2.0 |
Antioxidants/pharmacology | 2 | 1.0 |
DNA/metabolism | 7 | 0.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
Bile Acids and Salts/metabolism | 3 | 8.0 |
Dietary Fiber/*pharmacology | 2 | 40.0 |
Feces/chemistry | 2 | 4.0 |
Myelin P2 Protein/*genetics | 2 | 11.0 |
Aging/*blood | 4 | 5.0 |
*Life Style | 2 | 3.0 |
Apolipoproteins B/blood/*standards | 2 | 100.0 |
Recombinant Proteins/secretion | 2 | 25.0 |
Spodoptera | 2 | 0.0 |
Gonadal Steroid Hormones/blood | 2 | 2.0 |
Pyrroles/adverse effects/*therapeutic use | 3 | 50.0 |
Carrier Proteins/chemistry/*metabolism | 3 | 3.0 |
Apolipoproteins B/*biosynthesis/metabolism | 3 | 100.0 |
Cholesterol/*biosynthesis/blood | 3 | 42.0 |
*Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 52.0 |
Isomerism | 4 | 1.0 |
Lovastatin/*analogs & derivatives/pharmacology | 2 | 18.0 |
Simvastatin | 12 | 41.0 |
Oxygen Consumption | 2 | 0.0 |
Physical Endurance/*physiology | 2 | 4.0 |
*Sex Characteristics | 3 | 2.0 |
Apolipoproteins B/*biosynthesis/blood/*genetics | 2 | 100.0 |
Hypobetalipoproteinemia/*blood/*genetics | 3 | 100.0 |
Europe | 4 | 1.0 |
Cross-Linking Reagents | 3 | 0.0 |
*Heat-Shock Proteins | 2 | 3.0 |
Absorption | 2 | 1.0 |
Eating/physiology | 4 | 7.0 |
Hypobetalipoproteinemia/*genetics/metabolism | 2 | 100.0 |
Contraceptives, Oral/pharmacology | 2 | 11.0 |
Cysteine Endopeptidases/*physiology | 2 | 6.0 |
Multienzyme Complexes/*physiology | 2 | 10.0 |
Proteins/metabolism | 3 | 0.0 |
Heptanoic Acids/adverse effects/*therapeutic use | 2 | 66.0 |
Fatty Acids/analysis | 3 | 10.0 |
Protein Conformation/drug effects | 4 | 7.0 |
Trypsin/metabolism | 3 | 2.0 |
Apolipoproteins B/*metabolism/pharmacokinetics | 2 | 100.0 |
Acylation | 2 | 2.0 |
Blood Proteins/*metabolism | 2 | 1.0 |
Coronary Artery Bypass | 2 | 3.0 |
*Food | 3 | 3.0 |
Macrophages, Peritoneal/*metabolism | 2 | 9.0 |
Diabetes Mellitus, Type 2/*metabolism | 4 | 8.0 |
Epithelium/metabolism | 2 | 0.0 |
Sterols/biosynthesis | 2 | 28.0 |
Copper | 3 | 15.0 |
Malondialdehyde | 2 | 66.0 |
Biological Markers/*blood | 3 | 1.0 |
Coronary Arteriosclerosis/blood | 2 | 66.0 |
Myocardial Infarction/*blood | 4 | 6.0 |
Antilipemic Agents/*pharmacology/therapeutic use | 4 | 80.0 |
Lipoproteins/blood/chemistry | 4 | 36.0 |
Coronary Disease/*blood/genetics | 4 | 50.0 |
Epitopes/analysis/immunology | 2 | 10.0 |
Apolipoproteins B/*analysis/immunology | 2 | 100.0 |
Kidney/metabolism | 2 | 0.0 |
Crystallization | 2 | 0.0 |
Lipoproteins, LDL/*chemistry/classification | 2 | 100.0 |
Anticholesteremic Agents/adverse effects/*therapeutic use | 2 | 28.0 |
Peritoneal Dialysis, Continuous Ambulatory | 2 | 4.0 |
*Genotype | 3 | 1.0 |
Hypercholesterolemia, Familial/*blood/genetics | 2 | 50.0 |
*Phenotype | 4 | 1.0 |
DNA/analysis | 9 | 1.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
Heat-Shock Proteins 70/metabolism | 2 | 3.0 |
Apolipoprotein A-I/genetics | 3 | 15.0 |
Clinical Trials | 3 | 0.0 |
Lipase/*deficiency | 3 | 50.0 |
Lipoprotein Lipase/*deficiency | 2 | 18.0 |
Brefeldin A | 5 | 10.0 |
Cyclopentanes/pharmacology | 5 | 10.0 |
Cholesterol, Dietary/administration & dosage | 2 | 7.0 |
Lipoproteins, LDL | 2 | 22.0 |
Cryopreservation | 2 | 1.0 |
Microscopy, Electron/*methods | 2 | 33.0 |
Arginine/genetics | 3 | 1.0 |
Glutamine/genetics | 3 | 6.0 |
*Polymorphism, Single-Stranded Conformational | 2 | 1.0 |
Longevity/*genetics | 3 | 8.0 |
Micelles | 3 | 6.0 |
Estradiol/*pharmacology | 3 | 1.0 |
Oxidation-Reduction/drug effects | 6 | 7.0 |
Immunochemistry | 7 | 3.0 |
Vitamin E/physiology | 2 | 66.0 |
Blood Pressure/*genetics | 2 | 3.0 |
Cholesterol/blood/*metabolism | 5 | 22.0 |
Coronary Arteriosclerosis/*blood | 2 | 14.0 |
Cysteine/genetics | 3 | 2.0 |
Glomerular Filtration Rate | 5 | 4.0 |
Apolipoproteins B/blood/*immunology | 3 | 100.0 |
Precipitation | 6 | 3.0 |
Intestinal Mucosa/secretion | 2 | 40.0 |
*Triglycerides | 2 | 50.0 |
Lovastatin/*analogs & derivatives/therapeutic use | 5 | 50.0 |
Sterol O-Acyltransferase/blood | 2 | 28.0 |
Coronary Disease/*etiology | 2 | 7.0 |
Apolipoproteins/*analysis | 5 | 31.0 |
Growth Hormone/*therapeutic use | 2 | 10.0 |
Hemoglobin A, Glycosylated/metabolism | 3 | 2.0 |
Insulin-Like Growth Factor I/metabolism | 2 | 1.0 |
Apolipoproteins B/*blood/genetics | 4 | 100.0 |
Protein Disulfide-Isomerase | 2 | 10.0 |
Apolipoproteins B/*isolation & purification | 3 | 100.0 |
Cholesterol/blood/metabolism | 2 | 10.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
Lipoproteins, VLDL/secretion | 3 | 50.0 |
Hypercholesterolemia/*blood/drug therapy | 3 | 37.0 |
Lovastatin/*analogs & derivatives/pharmacology/therapeutic use | 3 | 100.0 |
beta-Galactosidase/genetics | 2 | 1.0 |
Breast Feeding | 2 | 3.0 |
Insulin Resistance/*genetics | 2 | 2.0 |
Lysine | 3 | 6.0 |
Gemfibrozil/*pharmacology/therapeutic use | 2 | 50.0 |
Obesity/epidemiology | 2 | 8.0 |
Vitamin E/*pharmacology | 3 | 14.0 |
Cornea/*metabolism/ultrastructure | 2 | 100.0 |
Oleic Acid | 22 | 36.0 |
Oleic Acids/pharmacology | 10 | 47.0 |
Peptide Fragments/chemistry/genetics/metabolism | 2 | 2.0 |
Arteriosclerosis/*metabolism/pathology | 7 | 17.0 |
Apolipoprotein A-II/*metabolism | 3 | 27.0 |
Kringles | 5 | 33.0 |
Lipoproteins, LDL/*blood/isolation & purification | 5 | 41.0 |
Apolipoproteins B/biosynthesis/secretion | 4 | 100.0 |
Lipoproteins/*secretion | 3 | 37.0 |
Lipoproteins, LDL/pharmacology | 2 | 4.0 |
Oleic Acids/metabolism | 6 | 28.0 |
Triglycerides/biosynthesis/secretion | 3 | 75.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 2 | 1.0 |
Cluster Analysis | 2 | 1.0 |
Diabetes Mellitus, Type 1/*blood/physiopathology/urine | 2 | 40.0 |
Heparin | 4 | 5.0 |
Lipoproteins/*blood/isolation & purification | 4 | 66.0 |
Endothelium, Vascular/drug effects/*metabolism | 2 | 2.0 |
Gene Library | 2 | 0.0 |
Abetalipoproteinemia/*blood | 2 | 50.0 |
Epitopes/analysis | 4 | 1.0 |
Exercise/*physiology | 2 | 0.0 |
Lipoproteins, VLDL Cholesterol/*blood | 3 | 42.0 |
Procetofen/*pharmacology/therapeutic use | 2 | 66.0 |
Hydroxymethylglutaryl CoA Reductases/genetics | 2 | 25.0 |
Lipids/secretion | 2 | 66.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Carrier Proteins/*chemistry/metabolism | 2 | 5.0 |
Lipoproteins, VLDL/pharmacology | 3 | 18.0 |
Adsorption | 2 | 1.0 |
Blood Proteins/metabolism | 3 | 1.0 |
Heat | 3 | 0.0 |
Lipoproteins, LDL/blood/isolation & purification | 5 | 83.0 |
Lipoproteins, VLDL/blood/isolation & purification | 4 | 66.0 |
beta-Fructofuranosidase | 2 | 28.0 |
Lipoprotein(a)/*chemistry/metabolism | 2 | 100.0 |
Oligodeoxyribonucleotides | 5 | 0.0 |
RNA/*metabolism | 2 | 3.0 |
DNA Fingerprinting | 2 | 1.0 |
Glomerulosclerosis, Focal/*complications | 2 | 100.0 |
Coronary Disease/epidemiology | 2 | 10.0 |
Lipoproteins/genetics | 3 | 37.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Sterols/metabolism | 2 | 11.0 |
Feasibility Studies | 2 | 0.0 |
Liver/cytology/metabolism | 3 | 6.0 |
Lipoprotein(a)/*chemistry | 3 | 100.0 |
Cholestyramine/therapeutic use | 2 | 28.0 |
Hyperlipidemia/blood/drug therapy | 2 | 25.0 |
Lipoproteins/blood/*drug effects | 4 | 40.0 |
Liver/*chemistry | 3 | 8.0 |
Liver Cirrhosis, Alcoholic/metabolism | 2 | 28.0 |
RNA, Messenger/*analysis | 5 | 1.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 25.0 |
*Gene Deletion | 3 | 0.0 |
Triglycerides/*analysis | 3 | 60.0 |
Apolipoproteins/isolation & purification/*metabolism | 2 | 100.0 |
Clofibrate/pharmacology | 2 | 9.0 |
Thyroxine/blood | 2 | 0.0 |
Lipoproteins/*analysis | 6 | 31.0 |
Apolipoproteins B | 33 | 76.0 |
Copper/*pharmacology | 3 | 16.0 |
Lipoproteins/*biosynthesis/secretion | 2 | 100.0 |
Liver Neoplasms, Experimental/metabolism | 4 | 20.0 |
Codon/genetics | 5 | 1.0 |
Diabetes Mellitus, Type 1/*metabolism | 2 | 3.0 |
*Frameshift Mutation | 3 | 1.0 |
Deoxyribonuclease I | 2 | 1.0 |
Antibody Specificity | 9 | 0.0 |
*Enzyme-Linked Immunosorbent Assay/statistics & numerical data | 2 | 100.0 |
Heparin/*therapeutic use | 2 | 8.0 |
Hypercholesterolemia/blood/genetics | 2 | 66.0 |
Binding Sites, Antibody | 6 | 1.0 |
Lipoproteins, LDL/*chemistry/immunology | 2 | 100.0 |
Asian Continental Ancestry Group/*genetics | 4 | 1.0 |
Radioisotope Dilution Technique | 2 | 6.0 |
Calcium/*metabolism | 2 | 0.0 |
Apolipoproteins E/*chemistry/metabolism | 2 | 22.0 |
Glucose/pharmacology | 4 | 3.0 |
Oleic Acids/*pharmacology | 5 | 33.0 |
Hypercholesterolemia, Familial/blood/*drug therapy | 3 | 21.0 |
Lipid Peroxidation/*drug effects | 4 | 12.0 |
Thiobarbituric Acid Reactive Substances | 2 | 28.0 |
Triglycerides/genetics | 3 | 100.0 |
Cell Membrane/*metabolism | 3 | 1.0 |
Progesterone/pharmacology | 2 | 1.0 |
Trifluoperazine/pharmacology | 2 | 3.0 |
Calcium/*blood | 2 | 2.0 |
Copper/blood | 2 | 8.0 |
Kidney Failure, Chronic/*metabolism/therapy | 2 | 14.0 |
Epitopes | 6 | 0.0 |
Apolipoproteins E/analysis | 5 | 31.0 |
Depression, Chemical | 2 | 1.0 |
Peptide Fragments/genetics | 2 | 2.0 |
Vitamin E/*metabolism | 2 | 20.0 |
Eicosapentaenoic Acid/*pharmacology | 2 | 15.0 |
*Heterozygote Detection | 2 | 1.0 |
Immunodiffusion | 15 | 5.0 |
Delayed-Action Preparations | 2 | 1.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Apolipoproteins B/*blood/immunology | 2 | 100.0 |
*Immunoassay | 3 | 21.0 |
Indians, North American | 3 | 9.0 |
*Dietary Fats | 2 | 9.0 |
Asia | 2 | 2.0 |
Arteries/metabolism | 2 | 12.0 |
Lipoproteins, HDL/chemistry/*metabolism | 2 | 33.0 |
Monensin/pharmacology | 4 | 7.0 |
Diabetes Complications | 5 | 3.0 |
Hypertension/complications | 2 | 3.0 |
Obesity/complications | 2 | 4.0 |
Parents | 2 | 2.0 |
Twins, Monozygotic/*genetics | 2 | 10.0 |
Contraceptives, Oral/*pharmacology | 2 | 9.0 |
Cardiovascular Diseases/blood/etiology/mortality | 2 | 100.0 |
DNA Probes | 6 | 0.0 |
Genes, Structural | 11 | 1.0 |
*Biological Markers | 2 | 1.0 |
Louisiana | 3 | 15.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Pregnancy/*blood | 2 | 1.0 |
Apolipoproteins B/*biosynthesis/genetics/metabolism | 3 | 100.0 |
Hyperlipidemia/blood | 6 | 15.0 |
Lovastatin/pharmacology | 3 | 8.0 |
Hydrocephalus/*genetics | 2 | 11.0 |
Apolipoproteins B/pharmacokinetics | 2 | 66.0 |
Coronary Disease/*blood/radiography | 4 | 50.0 |
Lovastatin/*pharmacology/therapeutic use | 2 | 50.0 |
Apolipoprotein A-II/metabolism | 2 | 14.0 |
Hyperthyroidism/*blood | 2 | 10.0 |
Hypothyroidism/*blood | 2 | 7.0 |
Thyroid Hormones/blood | 2 | 2.0 |
Immunoelectrophoresis | 8 | 3.0 |
*Genes | 2 | 0.0 |
Endocytosis | 5 | 1.0 |
Lysine/metabolism | 3 | 4.0 |
Malondialdehyde/metabolism | 2 | 7.0 |
Quality Control | 2 | 1.0 |
Apolipoproteins B/metabolism/*secretion | 2 | 100.0 |
Epitopes/metabolism | 2 | 3.0 |
Diabetes Mellitus/*blood | 3 | 3.0 |
Metabolic Clearance Rate | 7 | 2.0 |
Haplorhini | 2 | 0.0 |
Coronary Disease/prevention & control | 2 | 20.0 |
Diabetes Mellitus, Type 1/*blood | 5 | 3.0 |
Lipoproteins, LDL/*drug effects/*metabolism | 2 | 40.0 |
Peptidyl-Dipeptidase A/blood/*genetics | 2 | 4.0 |
Vitamin E/*blood | 2 | 9.0 |
Apolipoproteins/genetics/metabolism | 2 | 50.0 |
Cross Reactions | 2 | 0.0 |
Epitopes/genetics | 2 | 2.0 |
Lipoproteins, LDL/*genetics | 2 | 33.0 |
Massachusetts | 2 | 11.0 |
Intestines/physiology | 4 | 57.0 |
Palmitic Acid | 2 | 12.0 |
Hyperinsulinism/*blood | 2 | 11.0 |
Cholesterol, Dietary/*pharmacology | 4 | 28.0 |
Calcimycin/pharmacology | 3 | 1.0 |
Nocodazole/pharmacology | 2 | 1.0 |
Fatty Acids, Nonesterified/metabolism | 3 | 9.0 |
*Sequence Deletion | 3 | 0.0 |
Kidney Failure, Chronic/*blood/*mortality/therapy | 2 | 66.0 |
Antibodies | 2 | 0.0 |
N-Acetylneuraminic Acid | 2 | 5.0 |
Skin/metabolism | 5 | 2.0 |
Diabetes Mellitus, Type 2/*blood/complications | 3 | 15.0 |
Apolipoproteins/analysis/genetics | 2 | 100.0 |
Repetitive Sequences, Nucleic Acid/genetics | 3 | 3.0 |
Parathyroid Hormone/blood | 2 | 1.0 |
Mass Screening | 4 | 2.0 |
Chylomicrons/metabolism | 3 | 13.0 |
Apolipoproteins C/metabolism | 2 | 15.0 |
Apolipoproteins A/*analysis/immunology | 2 | 100.0 |
Apolipoproteins B/analysis/*genetics | 3 | 100.0 |
Diabetes Mellitus, Type 2/complications | 2 | 9.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Nuclear Proteins/*metabolism | 3 | 0.0 |
*Phosphoproteins | 2 | 1.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid/*genetics | 2 | 1.0 |
Lipoproteins/*immunology | 3 | 17.0 |
Malondialdehyde/*pharmacology | 2 | 50.0 |
*Haplotypes | 3 | 1.0 |
Apolipoproteins B/*biosynthesis/blood | 2 | 100.0 |
Lipoproteins, VLDL/*biosynthesis/blood | 2 | 66.0 |
Repetitive Sequences, Nucleic Acid | 7 | 0.0 |
Heparin/*pharmacology | 3 | 2.0 |
Leucine/blood | 2 | 33.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Environment | 2 | 2.0 |
Coronary Disease/*blood/drug therapy | 2 | 50.0 |
Immunoglobulins, Fab/metabolism | 2 | 7.0 |
Methylation | 4 | 0.0 |
*Receptors, Immunologic | 2 | 1.0 |
Hyperlipidemia, Familial Combined/blood | 3 | 100.0 |
Lipoproteins, HDL/blood/isolation & purification | 2 | 40.0 |
Diabetic Diet | 3 | 9.0 |
Hypoglycemic Agents/therapeutic use | 2 | 4.0 |
Lipoproteins, LDL/analysis/*metabolism | 3 | 75.0 |
Hypercholesterolemia, Familial/blood/drug therapy | 3 | 50.0 |
Chemistry | 4 | 1.0 |
Immunologic Techniques | 5 | 1.0 |
Hypobetalipoproteinemia/blood/*genetics/*metabolism | 2 | 100.0 |
Intestinal Mucosa/*metabolism | 2 | 2.0 |
Hyperlipoproteinemia Type IV/blood | 3 | 30.0 |
DNA, Single-Stranded | 2 | 2.0 |
Photochemistry | 2 | 3.0 |
Apolipoprotein A-I/secretion | 2 | 66.0 |
Apolipoproteins/secretion | 2 | 50.0 |
Metabolic Clearance Rate/drug effects | 2 | 12.0 |
Lipoproteins/blood/*chemistry | 2 | 33.0 |
Testosterone/*pharmacology | 2 | 6.0 |
Peritoneal Cavity/cytology | 2 | 4.0 |
Receptors, Steroid/*metabolism | 2 | 3.0 |
Immunoglobulins, Fab/immunology | 2 | 1.0 |
Peptide Fragments/immunology | 3 | 1.0 |
Recombinant Fusion Proteins/immunology | 2 | 1.0 |
Triiodothyronine/*pharmacology | 2 | 4.0 |
Aldehydes/metabolism | 2 | 16.0 |
Lipoproteins/*biosynthesis/isolation & purification | 2 | 100.0 |
*Lipoproteins | 2 | 5.0 |
Hypolipoproteinemia/*genetics | 5 | 16.0 |
Lipoproteins, VLDL/*blood/metabolism | 3 | 75.0 |
Lipoproteins, LDL Cholesterol/*blood/genetics | 2 | 33.0 |
Apoproteins/*blood | 4 | 30.0 |
*Milk | 2 | 28.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
Lipoproteins, VLDL/*blood/isolation & purification | 3 | 60.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Leucine/administration & dosage/blood/metabolism | 2 | 100.0 |
Nutritional Status | 2 | 1.0 |
Antigen-Antibody Complex/*blood | 2 | 3.0 |
Blood Pressure/physiology | 2 | 1.0 |
*Eggs | 2 | 66.0 |
Fatty Acids, Unsaturated/blood | 2 | 28.0 |
DNA Fingerprinting/methods | 3 | 4.0 |
*Paternity | 3 | 4.0 |
Liver Neoplasms, Experimental/*metabolism | 2 | 20.0 |
Apolipoproteins/*analysis/blood | 3 | 75.0 |
Peptide Mapping | 2 | 0.0 |
Hypercholesterolemia, Familial/*blood | 5 | 29.0 |
Rats, Inbred Strains | 8 | 1.0 |
Receptors, LDL/immunology/*physiology | 2 | 100.0 |
ATP-Binding Cassette Transporters/*genetics | 3 | 1.0 |
Apolipoproteins/analysis/*metabolism | 2 | 66.0 |
*Mutation, Missense | 3 | 0.0 |
Macrophages/drug effects/metabolism | 2 | 4.0 |
Antibodies, Monoclonal/diagnostic use | 6 | 0.0 |
Chylomicrons/analysis | 2 | 100.0 |
Lipoproteins, VLDL/analysis | 7 | 63.0 |
Lipoproteins, LDL/*biosynthesis/blood | 2 | 100.0 |
Chromosome Deletion | 2 | 0.0 |
Apolipoprotein A-I | 39 | 35.0 |
Apolipoprotein A-II | 14 | 29.0 |
Organ Culture Techniques | 3 | 0.0 |
Antigen-Antibody Complex | 3 | 1.0 |
Nucleic Acid Hybridization | 11 | 0.0 |
Lipoproteins, VLDL/blood/chemistry | 3 | 75.0 |
Platelet Aggregation/drug effects | 2 | 0.0 |
Kuwait | 2 | 8.0 |
Lipoprotein(a) | 14 | 60.0 |
*DNA | 2 | 6.0 |
Polyethylene Glycols | 4 | 4.0 |
Tangier Disease/*blood/genetics | 2 | 66.0 |
Fetus | 2 | 0.0 |
*Genes, Regulator | 2 | 1.0 |
Water | 2 | 3.0 |
Arteriosclerosis/metabolism/*pathology | 2 | 28.0 |
Apolipoproteins A/analysis | 3 | 50.0 |
Antilipemic Agents/pharmacology/*therapeutic use | 2 | 28.0 |
Diabetes Mellitus, Type 2/drug therapy/*metabolism | 2 | 40.0 |
Dietary Carbohydrates/*metabolism | 2 | 18.0 |
Densitometry | 3 | 2.0 |
Apolipoproteins B/*blood/isolation & purification | 4 | 100.0 |
Phospholipids/*blood | 3 | 9.0 |
Apolipoproteins B/*genetics/immunology | 6 | 100.0 |
Genes | 5 | 2.0 |
Centrifugation, Density Gradient/methods | 2 | 16.0 |
Tumor Cells, Cultured/*metabolism | 2 | 6.0 |
Nucleotide Mapping | 2 | 4.0 |
Dietary Proteins/*administration & dosage | 2 | 7.0 |
*Exercise Therapy | 2 | 7.0 |
Ribonucleases | 2 | 4.0 |
Lipoproteins/immunology/*metabolism | 2 | 50.0 |
Peptide Fragments/analysis | 3 | 1.0 |
Apolipoproteins/biosynthesis/*genetics | 2 | 40.0 |
Apolipoproteins B/*immunology | 4 | 80.0 |
Buffers | 2 | 1.0 |
Apolipoproteins E/*blood/isolation & purification | 2 | 50.0 |
*Work | 2 | 40.0 |
*Work Schedule Tolerance | 2 | 33.0 |
Twins, Monozygotic/genetics | 2 | 12.0 |
RNA/isolation & purification | 2 | 3.0 |
Hemoglobin A, Glycosylated/*analysis | 2 | 0.0 |
Antibodies, Monoclonal/*immunology | 3 | 0.0 |
Lipoproteins, LDL/immunology | 7 | 41.0 |
Multienzyme Complexes/antagonists & inhibitors/*metabolism | 2 | 9.0 |
Blood Proteins/analysis | 2 | 1.0 |
Lipoproteins, LDL Cholesterol/*genetics | 2 | 66.0 |
Twins, Dizygotic | 3 | 8.0 |
Esters | 3 | 9.0 |
Risk | 9 | 1.0 |
Recombination, Genetic | 2 | 0.0 |
*Nephelometry and Turbidimetry | 2 | 50.0 |
Enterocytes/*metabolism | 2 | 25.0 |
Golgi Apparatus/*metabolism | 3 | 3.0 |
Apolipoproteins/*biosynthesis | 3 | 33.0 |
*Enzyme-Linked Immunosorbent Assay | 2 | 2.0 |
Hypercholesterolemia, Familial/blood | 5 | 31.0 |
Methods | 4 | 1.0 |
Receptors, Cell Surface/*metabolism | 7 | 1.0 |
Apolipoproteins A/blood/genetics | 2 | 100.0 |
Epitopes/*immunology | 2 | 0.0 |
Bacteriophage lambda/genetics | 2 | 4.0 |
RNA/analysis | 3 | 1.0 |
*Chromosomes, Human, Pair 2 | 2 | 0.0 |
DNA-Directed DNA Polymerase | 3 | 11.0 |
Lipid Metabolism, Inborn Errors/*drug therapy/metabolism | 2 | 100.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
*Apolipoproteins B | 2 | 66.0 |
*Databases, Nucleic Acid | 2 | 7.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Australia | 2 | 1.0 |
*Health Promotion | 2 | 6.0 |
Lipoproteins/blood/drug effects | 3 | 21.0 |
Gene Amplification | 2 | 0.0 |
Intestines/analysis | 2 | 40.0 |
Liver/analysis | 4 | 22.0 |
Taq Polymerase | 2 | 5.0 |
Intestines/*analysis | 2 | 25.0 |
Liver/*analysis | 3 | 23.0 |
Gene Expression Regulation/*genetics | 2 | 1.0 |
Creatine Kinase/blood | 2 | 1.0 |
Coronary Arteriosclerosis/blood/*genetics | 4 | 44.0 |
Fatty Acids, Nonesterified/pharmacology | 3 | 37.0 |
Plasma/*analysis | 2 | 25.0 |
Epitopes/*analysis | 4 | 2.0 |
*Codon | 2 | 4.0 |
Cholesterol/pharmacology | 2 | 13.0 |
Immune Sera | 2 | 0.0 |
Estradiol/*blood | 3 | 1.0 |
Tablets | 2 | 5.0 |
Dietary Fats/administration & dosage/*pharmacology | 2 | 15.0 |
Apolipoproteins/*blood/isolation & purification | 3 | 100.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Macaca mulatta | 2 | 0.0 |
Lipoproteins/*analysis/blood | 2 | 40.0 |
Lipoproteins, LDL/analysis | 5 | 55.0 |
Lipoproteins, VLDL Cholesterol | 4 | 30.0 |
Adenocarcinoma/*metabolism | 2 | 2.0 |
Colonic Neoplasms/*metabolism | 2 | 2.0 |
Epitopes/*genetics | 2 | 6.0 |
DNA Restriction Enzymes/diagnostic use | 2 | 5.0 |
Liver/physiology | 4 | 7.0 |
DNA Restriction Enzymes | 4 | 1.0 |
Chromatography, Gas | 2 | 2.0 |
Body Weight/drug effects | 2 | 1.0 |
Precipitation/methods | 2 | 100.0 |
Phosphatidylcholines/analysis | 2 | 14.0 |
Lipoproteins, VLDL/immunology | 2 | 66.0 |
Kidney Failure, Chronic/*blood/therapy | 2 | 3.0 |
Aldehydes/*metabolism | 2 | 14.0 |
Lipid Peroxides/metabolism | 2 | 11.0 |
Hypolipoproteinemia/*blood | 2 | 9.0 |
Lipoproteins, HDL/genetics | 3 | 50.0 |
Lipoproteins, HDL/immunology | 2 | 100.0 |
Carbohydrates/analysis | 2 | 3.0 |
Apolipoproteins B/*blood/diagnostic use | 2 | 100.0 |
Thrombin/pharmacology | 2 | 0.0 |
Apolipoproteins B/physiology | 3 | 100.0 |
Fatty Acids, Unsaturated/administration & dosage/*pharmacology | 2 | 100.0 |
Lipid Bilayers | 2 | 4.0 |
Collodion | 2 | 5.0 |
Electrophoresis/*methods | 2 | 8.0 |
Sepharose | 2 | 3.0 |
*Infant, Newborn | 2 | 4.0 |
Calorimetry, Differential Scanning | 3 | 9.0 |
Molecular Conformation | 2 | 0.0 |
Thermodynamics | 2 | 0.0 |
Apolipoproteins A/*blood/isolation & purification | 2 | 66.0 |
Dimyristoylphosphatidylcholine | 2 | 13.0 |
Solvents | 2 | 3.0 |
Proteins/analysis | 2 | 1.0 |
Receptors, Lipoprotein | 3 | 30.0 |
Ubiquitin/*metabolism | 2 | 1.0 |
Lipoproteins/*biosynthesis/blood | 2 | 100.0 |
Apolipoproteins E/blood/*metabolism | 2 | 33.0 |
Lipoproteins, HDL/blood/*metabolism | 2 | 18.0 |
Apolipoproteins/immunology | 2 | 100.0 |
C-Reactive Protein/*analysis | 2 | 0.0 |
Apolipoproteins/*isolation & purification | 2 | 66.0 |
*Lipoproteins, LDL/blood | 3 | 100.0 |
Carrier Proteins/*antagonists & inhibitors/metabolism | 2 | 20.0 |
Lipoproteins, HDL Cholesterol | 4 | 8.0 |
Cholesterol/genetics | 2 | 100.0 |
*Diseases in Twins | 2 | 6.0 |
Apolipoproteins E | 5 | 16.0 |
Arteriosclerosis/*blood | 2 | 9.0 |
Hyperlipoproteinemia Type III/*metabolism | 2 | 100.0 |
*Intestinal Absorption | 2 | 5.0 |
Apolipoproteins/*immunology | 2 | 50.0 |
*Apolipoproteins | 2 | 6.0 |
Receptors, LDL | 2 | 20.0 |
Fats, Unsaturated/*pharmacology | 2 | 100.0 |
Lipoproteins, HDL/*blood/isolation & purification | 2 | 20.0 |
Perfusion | 2 | 0.0 |
*Epidemiologic Methods | 2 | 15.0 |
Lipoproteins, LDL/immunology/*metabolism | 2 | 40.0 |
Arteries/*metabolism | 2 | 25.0 |
Intracranial Arteriosclerosis/*metabolism | 3 | 100.0 |
Apoproteins/*analysis | 2 | 66.0 |
Urea/metabolism | 2 | 4.0 |
